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ABSTRACT OF THE DISSERTATION
THE INFLUENCE OF NEUROCOGNITIVE IMPAIRMENT, ALCOHOL AND
OTHER DRUG (AOD) USE, AND PSYCHOSOCIAL FACTORS ON
ANTIRETROVIRAL TREATMENT ADHERENCE, SERVICE UTILIZATION AND
VIRAL LOAD AMONG HIV-SEROPOSITIVE ADULTS
by
Jennifer Attonito
Florida International University, 2013
Miami, Florida
Jessy G. Dévieux, Major Professor
Among people living with HIV (PLWH), adherence to antiretroviral therapy
(ART) can be affected by problems of neurocognitive (NC) impairment, stress, alcohol
and other drug (AOD) abuse, and other barriers. The aims of this research were to: (1)
examine factors associated with NC impairment, (2) explore relationships between
psychosocial variables with ART adherence and viral load (VL), and (3) evaluate the
efficacy of an evidence-based intervention in improving ART adherence, increasing
service utilization, and decreasing VL.
The first study (n=370) was cross sectional and used structural equation modeling
to test whether AOD use, years living with HIV, and time from HIV diagnosis to seeking
care were associated with poorer NC functioning. The second study (n=246) used similar
methods to test the hypothesis that stress, barriers to adherence, NC impairment, poor
social support, and AOD use were related to lower VL mediated by ART adherence. The
third study (n=243) evaluated an evidence-based, eight-session program to improve ART
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adherence, reduce VL, and increase service utilization in a randomized controlled trial.
Study participants were PLWH living in South Florida, 18 to 60 years old, with a history
of alcohol abuse enrolled from January 2009 through November 2012.
Secondary analysis of available data showed: (1) scores on interference with
executive functioning increased by 0.32 for each day of marijuana use and 1.18 for each
year living with HIV, but no association was found between alcohol use and NC
functioning; (2) each barrier to adherence was associated with a 10% decrease in
adherence to ART and a 0.42 unit increase in VL (log10) and the relationship between
barriers and VL was partially mediated by ART adherence; (3) participants in the
evidence-based program were more likely than the comparison group to report an
undetectable VL (OR=2.25, p<0.01) at 6 months, but not 3 months, post-intervention.
Psychosocial factors affect VL, but ART adherence is essential in achieving an
undetectable VL in PLWH.

	
  

vii

TABLE OF CONTENTS
CHAPTER

PAGE

CHAPTER I ........................................................................................................................ 1	
  
BACKGROUND............................................................................................................. 1	
  
Treatment for Human Immunodeficiency Virus (HIV) .............................................. 1	
  
HIV Treatment Adherence .......................................................................................... 1	
  
HIV-Associated Neurocognitive Impairment .............................................................. 5	
  
Alcohol and other Drug Use ........................................................................................ 8	
  
Stressful Life Events.................................................................................................. 12	
  
Social Support............................................................................................................ 13	
  
Statement of the Problem .......................................................................................... 15	
  
Study Aims and Hypotheses ...................................................................................... 16	
  
REFERENCES .............................................................................................................. 18	
  
CHAPTER II..................................................................................................................... 31	
  
METHODOLOGY ........................................................................................................ 31	
  
Data Source................................................................................................................ 31	
  
Participants ................................................................................................................ 32	
  
Compensation ............................................................................................................ 34	
  
Group Randomization................................................................................................ 34	
  
Treatment Condition: HHRP-A ................................................................................. 35	
  
Treatment Condition: Health Promotion Comparison............................................... 37	
  
Data Collection .......................................................................................................... 38	
  
Measurement Instruments.......................................................................................... 38	
  
Analysis ..................................................................................................................... 43	
  
Theoretical Underpinnings ........................................................................................ 45	
  
REFERENCES .............................................................................................................. 50	
  
CHAPTER III ................................................................................................................... 56	
  
TRANSITION TO MANUSCRIPT 1 ........................................................................... 56	
  
MANUSCRIPT 1: Exploring factors associated with neurocognitive impairment
among people living with HIV/AIDS ........................................................................... 58	
  
ABSTRACT .................................................................................................................. 58	
  
INTRODUCTION......................................................................................................... 60	
  
METHODS ................................................................................................................... 62	
  
Study Design ............................................................................................................. 62	
  
Measures: Independent Variables .............................................................................. 63	
  
Measures: Dependent (Outcome) Variables .............................................................. 64	
  
Analytic Strategy ....................................................................................................... 66	
  
RESULTS ..................................................................................................................... 67	
  
DISCUSSION ............................................................................................................... 73	
  
REFERENCES .............................................................................................................. 79	
  

	
  

viii

CHAPTER IV ................................................................................................................... 87	
  
TRANSITION TO MANUSCRIPT 2 ........................................................................... 87	
  
MANUSCRIPT 2: Testing a mediated biopsychosocial model to explain differences in
viral load among people living with HIV...................................................................... 90	
  
ABSTRACT .................................................................................................................. 90	
  
INTRODUCTION......................................................................................................... 92	
  
METHODS ................................................................................................................... 95	
  
Sample ....................................................................................................................... 95	
  
Measures .................................................................................................................... 96	
  
Analytic Strategy ..................................................................................................... 100	
  
RESULTS ................................................................................................................... 102	
  
DISCUSSION ............................................................................................................. 107	
  
REFERENCES ............................................................................................................ 112	
  
CHAPTER V .................................................................................................................. 123	
  
TRANSITION TO MANUSCRIPT 3 ......................................................................... 123	
  
MANUSCRIPT 3: Effectiveness of an evidence-based intervention in improving
treatment adherence, service utilization and viral load among HIV-seropositive adult
alcohol users ................................................................................................................ 124	
  
ABSTRACT ................................................................................................................ 124	
  
INTRODUCTION....................................................................................................... 126	
  
METHODS ................................................................................................................. 129	
  
Participants .............................................................................................................. 129	
  
Outcome measures................................................................................................... 130	
  
Process measures ..................................................................................................... 131	
  
Treatment conditions ............................................................................................... 133	
  
Analysis ................................................................................................................... 135	
  
RESULTS ................................................................................................................... 137	
  
Socio-demographics ................................................................................................ 137	
  
Receipt of intended level of treatment and retention ............................................... 138	
  
Outcomes ................................................................................................................. 139	
  
Processes.................................................................................................................. 140	
  
DISCUSSION ............................................................................................................. 143	
  
REFERENCES ............................................................................................................ 149	
  
CHAPTER VI ................................................................................................................. 157	
  
SUMMARY OF CONCLUSIONS ............................................................................. 157	
  
APPENDICES ................................................................................................................ 161	
  
VITA ............................................................................................................................... 169	
  

	
  

ix

LIST OF TABLES
TABLE

PAGE

Table 1.1 (1). Sociodemographic characteristics of participants at baseline (N=370) ..... 69	
  
Table 1.2 (2). Bivariate regression statistics, 95% confidence intervals and p-values
(N=370) ............................................................................................................................. 72
Table 1.3 (3). Unstandardized path coefficients, standard errors, 95% confidence
intervals, and p-values (N=370)........................................................................................ 73
	
  

Table 2.1 (1). Baseline sociodemographic characteristics of participants and descriptive
statistics of variables in the model (N=246) ................................................................... 103	
  
Table 2.2 (2). Neurocognitive scores for participants at baseline (N=246) .................... 103
Table 2.3 (3). Unstandardized path coefficients, standard errors, 95% confidence intervals
and p-values (N=246) ..................................................................................................... 106	
  
Table 2.4 (4). Correlation matrix for all variables in the model (N=246) ...................... 107	
  
Table 2.5 (5). Linear regressions, test for mediation (N=246) ....................................... 107
Table 3.1 (1). Descriptive characteristics of randomized sample (N=243) ................... 137	
  
Table 3.2 (2). Outcome and process values (N/% and Mean/SD) at all available time
points (N=243) ................................................................................................................ 141	
  
Table 3.3 (3). Rate ratios for 95% ART adherence and undetectable viral load, by study
assignment (N=243) ........................................................................................................ 142	
  
Table 3.4 (4). Effects (F statistics) for continuous variables by time and study assignment
(N=243) ........................................................................................................................... 142	
  
Table 3.5. Pearson and Spearman Rank correlations between outcome and process
variables at baseline, post-intervention, 3 months, and 6 months
(N=243) .......................................................................................................................... 143	
  

	
  

	
  

x

ACRONYMS AND ABBREVIATIONS

	
  

	
  

AIDS

Acquired Immune Deficiency Syndrome

AOD

Alcohol and Other Drug(s)

ART

Antiretroviral Therapy

AVLT

Auditory Verbal Learning Test

CBO

Community-Based Organization

CTT2

Color Trails Test 2

EBI

Evidence-Based Intervention(s)

HAART

Highly Active Antiretroviral Therapy

HAND

HIV-Associated Neurocognitive Disorders

HHRP-A

Holistic Health Recovery Program - Adapted

HIV

Human Immunodeficiency Virus

HPC

Health Promotion Comparison

IMB

Information Motivation Behavior Skills

NC

Neurocognitive

PLWH

People Living with HIV/AIDS

RCT

Randomized Controlled Trial

SCT

Short Category Test

TLFB

Time Line Follow-back

xi

CHAPTER I
BACKGROUND
Treatment for Human Immunodeficiency Virus (HIV)
Although over 600,000 people in the United States have died from complications
related to acquired immune deficiency syndrome (AIDS) since the beginning of the
epidemic, AIDS death rates have decreased dramatically since the mid-1990s. This
decline is due in great part to the advent of highly active antiretroviral therapy (HAART;
Centers for Disease Control and Prevention Division of HIV/AIDS, 2012a, 2012b).
Chemotherapy for human immunodeficiency virus (HIV) has evolved over the years
from no treatment to treatment with a single drug (AZT or Zidovudine) to dual-drug
therapy and, since 1996, to HAART (also referred to as ART). ART is defined as
treatment with at least three active anti-retroviral medications—typically two nucleoside
or nucleotide reverse transcriptase inhibitors (NRTI’s) plus a non-nucleoside reverse
transcriptase inhibitor (NNRTI) or a protease inhibitor (PI) or another NRTI—and is
often called the drug “cocktail” or triple-therapy (Thompson, Aberg, & Hoy, 2012).
Because each class of antiretroviral medications intercepts viral replication and
proliferation at different stages in the HIV life cycle, a combination of antiretrovirals is
considered to be most effective for achieving undetectable blood levels of the virus and
preventing the emergence of resistance.
HIV Treatment Adherence
HAART has essentially transformed HIV from a fatal to a chronic illness. Thus,
the goal of HIV care has shifted toward achieving long-term optimal health outcomes
through consistent adherence to ART. Proper ART adherence can stop viral replication,
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rendering virus levels undetectable in both blood and sexual fluids and reducing risk of
HIV transmission (Cohen & Chen, 2011; Volkow & Montaner, 2010). Optimal
adherence to ART—defined as following prescribed treatment at least 80% of the time
(Parienti et al., 2008)—directly improves health outcomes and is critical for successful
treatment (Bangsberg et al., 2000; Carpenter et al., 1997; Deeks, Smith, Holodniy, &
Kahn, 1997; Descamps & Flandre, 2000; Katzenstein, 1997; Paterson, Swindells, Mohr,
Brester, & Vergis, 2000).
Conversely, treatment interruption and inconsistent ART adherence is known to
result in poorer health outcomes and the emergence of treatment resistant strains of HIV,
reducing treatment options for an infected individual over time (Parienti et al., 2008;
Bangsberg et al., 2001). Additionally, these resistant strains may be transmitted to others
through infected body fluids, resulting in treatment failure and reduced treatment options
on a community level. Even in a time of heightened awareness of HIV in the U.S., about
50,000 people continue to be infected annually (Centers for Disease Control and
Prevention Division of HIV/AIDS, 2012). Because of the convincing body of knowledge
suggesting that consistent ART adherence can not only improve health outcomes for
individuals but also reduce HIV transmission at population levels, the Centers for Disease
Control and Prevention (CDC), National Institutes for Health (NIH), and Health
Resources and Services Administration (HRSA) have placed increasing priority on
improving treatment adherence and access to care for people living with HIV (PLWH;
White House Office of National AIDS Policy, 2010).
Adherence to ART is possibly the most important determinant of survival among
PLWH (Hogg et al. 2002) with earlier studies suggesting that as much as 95% adherence
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was necessary to achieve positive clinical outcomes with regimens used in the 1990s and
early 2000s (Bangsberg, Moss, & Deeks, 2004; Lucas, 2005; Paterson et al., 2000). Even
with the newest regimens, uninterrupted adherence of >80% is typically considered
essential to guarantee optimal virologic response (Parienti 2008). Furthermore,
inadequate treatment adherence is associated with increased mortality, drug resistance
and limited future treatment options for the patient, and increased risk of HIV
transmission to others (Bangsberg et al., 2001).
More recently, ART has been shown to be an effective means of HIV prevention.
Results from the nine-country HIV Prevention Trials Network (HPTN 052) revealed that
HIV-seropositive partners were significantly less likely to transmit the virus sexually to
uninfected partners if ART was initiated when CD4 counts were higher (350-499) than
levels considered absolute indications for ART initiation for patient’s health (CD4
count<350), indicating potential effectiveness of use of treatment as prevention of sexual
HIV transmission (Cohen et al. 2011). Other research has reported similar outcomes in
the use of treatment-as-prevention for HIV transmission related to injection drug use
(Choopanya et al., 2013; Wood, Kerr, & Marshall, 2009). While ART adherence is
strongly associated with viral suppression and reduction of HIV transmission to others,
this relationship may be related to the classes of antiretrovirals used (Bangsberg et al.,
2004; Katzenstein, 1997) and strain resistance to antiretrovirals used (Liao et al., 2013).
The reduction of VL has been shown to result in lower rates of new infection on a
community level (Das et al. 2010). However adequate viral suppression is achieved only
through treatment adherence by each individual. While efforts to simplify treatment
particularly to once-a-day one-pill ART, have been successful, ART regimens can still be
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complicated, requiring patients to take multiple doses daily of each medication in the
combination (Abgrall & The Antiretroviral Therapy Cohort Collaboration (ART-CC),
2012). Each medication may also carry specific dose-timing and storage requirements.
Different medications may need to be taken with food, without food, with water, or in an
order relative to other drugs in the combination (Catz, Kelly, Bogart, Benotsch, &
Mcauliffe, 2000).
Achieving the nearly perfect adherence recommended to suppress viral
replication, experience optimal health outcomes, and prevent HIV transmission can be
challenging. U.S. studies have reported that as few as 18% to 73% of participants were
non-adherent to antiretroviral therapy (Catz et al., 2000; Paterson et al., 2000; Tesoriero
et al., 2003). These percentages may be even lower for PLWHs dealing with
neurocognitive impairment, substance abuse problems, and added environmental and
psychosocial constraints. Additional predictors of poor ART adherence include poor
social support (Safren et al., 2001), mental health problems (Bottonari et al., 2012; Nel &
Kagee, 2011; Sherr, Clucas, Harding, Sibley, & Catalan, 2011), and alcohol abuse (Baum
et al., 2010; Bryant, 2006; Samet, Phillips, Horton, Traphagen, & Freedberg, 2004),
which will be discussed in greater detail below.
In addition to helping individual patients adhere to treatment regimens, the full
implementation of community-level treatment as prevention (i.e., “seek, test, treat,
retain”) requires stabilization of many policy and institutional factors, including
improving access to and utilization of available care (Mayer & Krakower, 2012).
Increasing access to care and optimizing health outcomes for PLWH is one of the three
primary goals of the National HIV/AIDS Strategy (White House Office of National AIDS
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Policy, 2010). It is estimated that as many as 30 percent of people diagnosed with HIV in
the U.S. are not accessing care (White House Office of National AIDS Policy, 2010).
Through adequate and consistent care, patients are better able to receive the support
necessary to achieve complete treatment adherence, sustain optimal health outcomes and,
ultimately, help to reduce the incidence of HIV.
HIV-Associated Neurocognitive Impairment
Over the next 20 years, neuropsychiatric disorders are estimated to exact a global
cost of $16.1 trillion with ‘‘dramatic impacts on productivity and quality of life’’ (Bloom
et al., 2012, p. 5). Mental, neurological, and substance use disorders are associated with
low rates of care utilization, poor treatment adherence and response, and increases in high
risk behaviors (Bass et al., 2012).
With HIV-positive individuals living longer because of increased availability and
use of HIV treatments, new neurologic syndromes often associated with HIV status are
emerging with greater frequency over the life span (Antinori et al., 2007; Durvasula,
Norman, & Malow, 2009; Norman, Basso, Kumar, & Malow, 2009; Palacio, Alvarez, &
Munoz-Fernandez, 2012). Thus, it is important to study the effects of neurocognitive
(NC) impairment on risk behaviors among PLWH. Since the advent of combination
ART, the incidence of HIV-associated dementia (HAD) has declined from 10-15%
(Janssen, Nwanyanwu, Selik, & Stehr-Green, 1992; J. McArthur & Grant, 1998) to 25% (Heaton et al., 2010; Robertson et al., 2007; Sacktor, 2002). However, milder forms
of HIV-associated neurocognitive disorders (HAND) have been reported in up to 40% of
this population, especially as HIV-positive individuals are living longer with the disease
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(Antinori et al., 2007; Durvasula et al., 2009; McArthur, 2004; Sacktor, 2002; Sacktor et
al., 2007).
HAND is divided into minor cognitive motor disorder (MCMD) and HAD
(Antinori et al., 2007). MCMD in turn is subdivided into asymptomatic neurocognitive
impairment (ANI) and mild neurocognitive disorder (MND). MND is accompanied by
mild interference in daily functioning, whereas ANI is not (Foley et al., 2010; Gandhi et
al., 2011). ANI and MND are both identified by performance scores at least one standard
deviation (SD) below the mean of normative scores in at least two cognitive domains:
attention-information, processing, language, abstraction-executive, complex perceptual
motor skills, memory, including learning and recall, simple motor skills or sensory
perceptual abilities. In contrast, HAD is characterized by marked neurocognitive
dysfunction (≥ 2 standard deviations below the mean normative scores) in at least two
cognitive domains. This level of cognitive impairment produces marked interference with
activities of daily living (Antinori et al., 2007; Foley et al., 2010; Gandhi et al., 2011;
Gisslén, Price, & Nilsson, 2011; Palacio et al., 2012).
The types of impairments exhibited by persons with these neurologic syndromes
can affect functioning at work or in everyday activities (Gandhi et al., 2011). Even
though HAD has become less frequent, HIV-positive individuals are still at risk for HIVassociated neurological complications. Two to five percent of HIV-positive individuals
are estimated to develop HAD and up to 37% will suffer a less severe ANI or MND
(Sacktor et al., 2002). Several of the neurocognitive deficits seen in patients with HAND
are believed to contribute to HIV risk behavior, affecting impulse control (Lopez, Smith,
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Meltzer, & Becker, 1999) and episodic memory functions that may impair the ability to
plan and execute intentions (Woods, Moore, Weber, & Grant, 2009).
HAND is mostly seen in advanced stages of HIV disease but can occur even in
PLWH with medically asymptomatic HIV infection (Grant et al., 1987; Heaton, Grant,
Butters, White, Kirkson, et al., 1995; White, Heaton, & Monsch, 1995). Increased
duration living with the virus, particularly during the acute phase of infection, has been
identified as partially responsible for NC impairment. Yet HAND has still been observed
to varying degrees among PLWH who have been consistently maintained at low-toundetectable VLs on ART (Simioni et al., 2010; Tozzi et al., 2007).
Multiple possible causes of HAND have been suggested: the inability of
commonly-used ART to penetrate the blood-brain barrier, with reduced levels in the
central nervous system (CNS) leading to incomplete viral suppression; brain damage
during acute HIV infection and prior to ART initiation; prolonged inflammatory response
and CNS immune reconstitution inflammatory syndrome (IRIS); possible neurotoxicity
of specific antiretrovirals; and exposure to other conditions associated with long-term
survival with HIV such as vascular dementia, Parkinson’s-related dementia, Alzheimer’s
disease and depression (Heaton et al., 2011; Johnson & Nath, 2011; Mateen & Mills,
2012). In addition, it has been suggested that HIV in the brain could develop increased
adaptation and neurovirulence in the presence of ART over time, potentially spreading to
other body tissues (Churchill & Nath, 2013).
Even the mildest form of HAND may be a precursor to more severe NC disorders
(McArthur, Steiner, Sacktor, & Nath, 2010). HAND in general can present clinically as
impairment in episodic memory, information processing, attention and executive

	
  

7

functions (Woods et al., 2009). Heaton (2011) found that patients in the pre-ART era and
those with later stage disease had poorer degrees of functioning in multiple NC domains.
Those in the ART era showed poorer functioning in cognitive domains of memory and
executive functioning. Visual working memory has been shown to improve with greater
viral suppression and improved immune function (Gupta et al., 2007). In patients
presenting with even milder forms of HAND, quality of life can be affected, with
struggles to perform activities of daily living, personal health care management and
control of risk behaviors (Malow et al., 2012; McArthur, 2004). In addition to impacting
risk behaviors and impulsivity, overall NC impairment has been linked with poorer ART
adherence among PLWH (Hinkin, Castellon, & Durvasula, 2002). Additionally, studies
have identified impairment in specific domains of functioning — such as verbal memory
(Applebaum, Reilly, et al., 2009; Wright et al., 2011) and executive functioning (Hinkin
& Hardy, 2004; Waldrop-Valverde, Jones, Gould, Kumar, & Ownby, 2010) — associated
with deficiencies in ART adherence. Whereas memory and information processing may
affect patients’ ability to understand complex medication information, executive
functioning may impact patients’ ability to make personal medication decisions and
manage the myriad life complexities that interfere with a treatment regimen.
Alcohol and other Drug Use
Studies have reported that more than 50% of HIV-infected clinic-based samples
reported illicit drug and heavy alcohol use (Bing et al., 2001; Martin et al., 2004; Samet
et al., 2004). Each additional substance use disorder contributes to poorer health
outcomes and is associated with decreased access to and use of health care and reduced
likelihood of being prescribed and/or adhering to ART (Bruce & Altice, 2007).
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HIV and alcohol abuse are considered to be converging epidemics and, as a result,
a greater number of individuals are at risk for alcohol use disorders, HIV infection and
rapid progression to AIDS (Bryant, 2006). Shared high-risk environments and behaviors,
as well as shared individual characteristics, have contributed to the HIV and alcohol
abuse epidemics, creating a synergistic phenomenon (Bryant, Nelson, Braithwaite, &
Roach, 2010; Bryant, 2006). In non-HIV clinic samples, 20-30% of patients are reported
to have met criteria for past or present alcohol problems (Buchsbaum, Buchanan, Centor,
Schnoll, & Lawton, 1991; Cleary, Miller, Bush, Warburg, & Delbanco, Aronson, 1988;
Fleming, Manwell, Barry, & Johnson, 1998). Furthermore, studies of HIV-infected clinic
patients have reported that more than 50% reported heavy alcohol use (Martin et al.,
2004; Samet et al., 2004). In a longitudinal cohort study of HIV-positive veterans, 33%
reported binge drinking and 32% had a clinical diagnosis of alcohol addiction or
dependence (Justice, Dombrowski, & Conigliaro, 2006).
Alcohol influences the complex decision-making process to engage in acts that
place one at risk for acquiring and transmitting HIV and other STIs (Bryant, 2006). Both
the degree of alcohol intoxication and history of alcohol abuse tend to be associated with
involvement in more risk behaviors (Bryant, 2006). Alcohol misuse and abuse have other
deleterious physical and mental health outcomes (Conigliaro, Gordon, McGinnis,
Rabeneck, & Justice, 2003; Justice et al., 2004) as well as hindering adherence to
healthcare recommendations, particularly medication regimens (Baum et al., 2010;
Bryant, 2006; Samet, Horton, Meli, Freedberg, & Palepu, 2004). Research shows that
severity of alcohol use is correlated with levels of ART non-adherence (Cook et al.,
2001).
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Several reasons have been cited for the negative impact of active alcohol use on
ART adherence (Lucas, Gebo, Chaisson, & Moore, 2002), including: (a) lifestyle
instability not conducive to ART (Sherer, 1998); (b) poor social support and mistrust of
the medical establishment (O’Connor, Selwyn, & Schottenfeld, 1994); (c) non-adherence
to scheduled clinic visits (Lucas et al., 2002); and (d) coexisting mental health disorders
that act as further barriers to adherence (Batki, Ferrando, Sorensen, & Wall, 1996). HIVinfected patients have also reported stopping treatment when drinking because of beliefs
about the toxicity of drinking while on ART (Kalichman et al., 2012; Sankar,
Wunderlich, Neufeld, & Luborsky, 2007). While there is evidence of combined or
enhanced toxicity effects, optimal ART adherence remains advised for HIV-positive
alcohol users (Braithwaite & Bryant, 2000). Although no consistent associations between
gender and ART adherence have been found, it should be noted that women may be more
adversely affected by alcohol abuse in terms of ART adherence (Applebaum, Richardson,
Brady, Brief, & Keane, 2009; Berg & Demas, 2004).
Alcohol abuse frequently co-occurs with HIV and may further impair NC
functioning among PLWH, however evidence of interactions between AOD use and HIV
upon NC performance has varied. Studies have reported that more than 50% of HIVinfected clinic patients reported heavy alcohol use (Martin et al., 2004; Samet et al.,
2004) and that up to 80% of people with alcohol use disorders may suffer from some
degree of NC impairment (Bates, Bowden, & Barry, 2002). Among individuals with HIV
infection and drug and alcohol use disorders, impaired verbal working memory
(Farinpour et al., 2000), impaired auditory working memory, and enhanced cognitive
impulsivity have been observed (Martin et al., 2004). Additionally, synergistic negative
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effects of HIV and heavy alcohol use together have been observed in motor and visual
spatial tasks (Rothlind et al., 2005). Alcohol use and HIV progression compromise
information processing, executive functioning, and emotion regulatory functions that may
be important in adhering to safe sex practices and other preventive behavior (Bryant,
2006). Alternately, several studies have been unable to identify interactions between drug
use and HIV upon NC performance (Bornstein et al., 1993; Concha et al., 1992;
Durvasula, Miller, Myers, & Wyatt, 2001; Selnes, Galai, McArthur, & Cohn, 1997).
Compounding the direct effects of NC impairment on ART adherence, substance use may
contribute further to substandard ART adherence (Hinkin et al., 2002; Rothlind et al.,
2005).
Alcohol use has been shown to play a possible confounding role in the assessment
of NC impairment among PLWH (Justice et al., 2004). In order to deliver targeted and
effective clinical care as well as HIV risk reduction and treatment adherence
interventions, it is important to understand not only specific domains of impairment
associated with HIV infection and alcohol abuse but also the effects of any potential
interactions between these two commonly coexisting conditions.
Although most research on the use of illicit substances and HIV infection center
upon injection drug use, marijuana and cocaine are reported to be the most commonlyused illicit substances among PLWH (Cook et al., 2001; Korthuis et al., 2008; Kuo et al.,
2004). Substantive evidence has linked general illicit drug use and ART non-adherence
(Lucas et al., 2006); however, research regarding adherence and marijuana use in
particular is mixed. Research on medical cannabis use has shown that participants report
considerable symptom relief (Prentiss, Power, Balmas, Tzuang, & Israelski, 2004), but
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several studies indicate that adherence rates are nonetheless lower for marijuana users
(Corless et al., 2009; Tucker, Burnam, Sherbourne, Kung, & Gifford, 2003). Conversely,
De Jong et al. (2005) observed greater ART adherence among participants who used
marijuana medicinally as opposed to recreationally. Research concerning marijuana use’s
impact on virologic, immunologic and other health markers among PLWH remains
limited. Research examining psychostimulants such as cocaine and methamphetamines,
however, has consistently shown an association with decreased adherence (Arnsten et al.,
2002; Hinkin et al., 2007; Tucker et al., 2003). Cocaine use may also be directly
associated with higher VLs (Arnsten et al., 2002).
Stressful Life Events
Life stress is a contextual variable commonly associated with risk and protective
health behaviors such as ART adherence (Chesney, Morin, & Sherr, 2000). According to
a 2010 CDC white paper on social determinants of HIV/AIDS in the U.S., distribution of
power and resources affect environmental conditions such as housing and social support;
social and physical environments, and availability, cost of, and access to healthcare
services and contribute as pathways to HIV infection or barriers to overall health
(Koopman et al., 2000). High levels of perceived stress among PLWH have been
associated with lower income, and financial difficulty is one of the most frequently
reported stressful events among PLWH (Mugavero et al., 2009; Reif et al., 2011). Other
stressful life events are exceedingly common in the lives of PLWH and are negatively
associated with antiretroviral medication adherence and treatment outcomes.
Associations between stress and substance abuse also have been identified, but the
exact relationship remains somewhat elusive. A review of animal studies identified
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several neurobiological connections between the changes in the brain produced by both
acute and chronic alcohol and other drug (AOD) use resulting from the introduction of
stressors (Piazza & Moal, 1998). Identifying relationships between stress and alcohol use
in clinical settings has been more challenging, in part because of inherent limitations in
attempting to conduct research with alcoholic participants (Brady & Sonne, 1999;
Russell, Cooper, Frone, & Peirce, 1999). Patients may vary in their likelihood of drinking
in response to stress, suggesting that individual factors moderate the relationship between
stress and alcohol use. However, in some studies, exposure to stressors has been
consistently associated with increased alcohol use, particularly as an avoidance coping
mechanism (Brady & Sonne, 1999; Russell et al., 1999). This relationship may indicate
that, in addition to directly affecting ART adherence, stress may also act through alcohol
to affect ART adherence.
Social Support
Stronger social support is known to reduce one’s reliance on avoidance coping
strategies and dampen the effects of stress in some situations (Heaney & Israel, 1997).
The term “social support” is typically used to describe mechanisms by which
interpersonal relationships may buffer a person against a stressful environment (Cohen &
McKay, 1985). Social support is a multidimensional construct and can involve networks
of individuals providing different modes of support: “(1) emotional support (the
expression of positive affect, empathetic understanding, and the encouragement of
expressions of feelings), (2) informational support (the offering of advice, information,
guidance or feedback), (3) tangible support (the provision of material aid or behavioral
assistance), (4) positive social interaction (the availability of other persons to do fun
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things with you), and (5) affectionate support (involving expressions of love and
affection)”(Sherbourne & Stewart, 1991, p. 707). Researchers have identified these
modes of support as influential in understanding health behaviors, and have suggested
that they be matched to the other factors examined in a given study in order to detect a
relationship (House & Kahn, 1985). For example, if the primary area of social support
perceived by the participant is “emotional,” its buffering effect may not be observable if
the actual form of social support needed to achieve an outcome is “tangible” (Cohen &
McKay, 1985).
The positive association between social support and adherence to ART regimens
among PLWH is well documented (Catz et al., 2000; Diiorio et al., 2009; Gordillo, del
Amo, Soriano, & González-Lahoz, 1999; Holzemer, 1999; Safren et al., 2001; Samet et
al., 2004; Simoni, Frick, & Huang, 2006; Singh et al., 1999), although few studies have
focused on specific roles and mechanisms of social support. A meta-analysis found that,
among people with different diseases, practical support was a much stronger predictor of
treatment adherence than emotional support (DiMatteo, 2004), but this analysis excluded
studies that involved substance abusing populations. Further, it has been found that
emotional support was a stronger predictor of medical care utilization (Broadhead,
Gehlbach, & Kaplan, 1989) and functional (e.g. financial) support was more closely
associated with treatment access (Knowlton et al., 2001). One study found that social
support did not directly influence ART adherence among PLWH, but instead acted
through the mediators, depression and self-efficacy (Diiorio et al., 2009). Similarly
Simoni, Frick, and Huang (2006) found that social support operated through affect and
spirituality in its relationship with efficacy to adhere to ART. Less present in the
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literature are studies examining the role of social support as a moderator, buffering the
effects of factors such as substance abuse, NC impairment, and stress on the outcomes of
ART adherence and response.
Statement of the Problem
While there is a greater understanding of HAND and the domains affected by
HIV, there is also an increasing frequency with which NC impairment is experienced by
PLWH today. Hence it becomes increasingly important to explore areas of daily
functioning that are potentially influenced by HAND. The increasing value being placed
upon ART as treatment and prevention on individual and community levels, both
nationally and internationally, underscores the importance of exploring the relationship
between NC impairment and ART adherence in the lives of PLWH. However, health
behaviors like ART adherence are not enacted in isolation; they are impacted by many
psychological, biological, and social factors. Complex contributions of common factors
such as alcohol use, life stress, and social support upon ART adherence must also be
taken into account. Only from a biopsychosocial perspective can we assess a “real world”
environment, achieving a broad perspective of the myriad influences on ART adherence
and service utilization in the lives of PLWH. According to Applebaum (2009, p.455),
“Given the extent of neuropsychological impairment [among HIV-positive substance
abusers], future studies should examine the degree to which the impact of
neuropsychological impairment may moderate interventions for this population, and the
extent to which skills to cope with neuropsychological problems may boost the potential
efficacy of such interventions.”
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Study Aims and Hypotheses
The overarching question to be answered in this research was: To what extent do
psychosocial factors — including neurocognitive impairment, drug use, and alcohol use
— influence ART adherence, service utilization and VL at baseline and following an
evidence-based intervention among HIV-positive alcohol abusers? Three study aims and
accompanying hypotheses were proposed to facilitate answering this question:
Aim 1
To determine the degree to which alcohol use, drug use, time from HIV diagnosis
to treatment, and years living with HIV affect three measures of neurocognitive
functioning among HIV-seropositive adult alcohol abusers at a single time point.
Hypothesis 1a: Greater alcohol, marijuana, and cocaine use will be associated
with increased neurocognitive impairment.
Hypothesis 1b: Living longer with HIV and waiting longer after HIV diagnosis to
seek treatment will be associated with increased neurocognitive impairment.
Aim 2
To explore the degree to which stress, social support and barriers impact ART
adherence and VL among HIV-seropositive adult alcohol users at baseline.
Hypothesis 2a: Greater perceived stress will be associated with higher VL.
Hypothesis 2b: Greater social support will be associated with lower VL.
Hypothesis 2c: More barriers to adherence will be associated with higher VL.
Hypothesis 2d: The above relationships with VL will be partially mediated by
ART adherence.
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Hypothesis 2e: Relationships between psychosocial factors and outcomes of ART
adherence and VL will be moderated by behavioral and cognitive variables:
alcohol use, marijuana use and neurocognitive impairment.
Aim 3
To evaluate the effectiveness of the adapted Holistic Health Recovery Program
(HHRP-A) on improving treatment adherence, service utilization and health outcomes
(VL) among HIV-seropositive adult alcohol users.
Hypothesis 3a: Greater improvement in ART adherence, VL, and service
utilization will be observed in the experimental condition than in the comparison
condition.
Hypothesis 3b: Greater reduction in perceived stress and increase in social
support will be observed in the experimental condition than in the comparison
condition.
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CHAPTER II
METHODOLOGY
Using data from a parent study described below, the three following manuscripts
mirror the three aims already described. Each paper draws from the same parent study,
but each has a different sample size, utilizes a different set of measures and employs
different analytic techniques. This dissertation study was approved by the Florida
International University Institutional Review Board (IRB-13-0072) most recently on
September 28, 2013.
Data Source
To address the research aims proposed in this dissertation, data were analyzed
from an NIH-funded parent study conducted by Dr. Jessy G. Dévieux (and the late Dr.
Robert Malow) titled “Intervening with HIV+ Alcohol Abusers: Influence of NeuroBehavioral Factors” (1 R01 AA017405). Their longitudinal (12-month follow-up)
randomized controlled trial attempted to reduce HIV sexual transmission risk and
substance use in 370 alcohol-using, HIV+ individuals. The experimental condition
included an adaptation of the Holistic Health Recovery Program (HHRP), an
information-motivation-behavioral skills (IMB)-guided, evidence-based intervention for
improving sexual risk and adherence outcomes for an HIV-positive addicted population
(Margolin, Avants, Warburton, Hawkins, & Shi, 2003). In this dissertation’s parent study,
the intervention was adapted for use in a culturally diverse, alcohol-abusing sample. The
adapted intervention (HHRP-A) is compared to a Health Promotion Comparison (HPC)
condition, which addresses common health problems, including personal hygiene and
healthy living.
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HHRP was developed in recognition of the need to provide an intervention
sensitive to neurobehavioral problems experienced in this population and was adapted for
this AOD-abusing population because it is the only CDC-identified intervention for an
HIV-positive, substance-abusing population that has been shown to reduce HIV
transmission risk behaviors among PLWH (Margolin et al., 2003). Whereas the original
HHRP addressed a methadone-maintained, drug abusing population, this adapted version
was specifically geared toward alcohol users, within an AOD prevention approach. In
developing HHRP-A, the research team attempted to achieve a reasonable balance
between maintaining fidelity to the original HHRP and enhancing key characteristics to
respond to the local context (e.g., community setting, clientele and cultural composition
or history, resources, priorities). The HHRP intervention had been adapted and evaluated
in multiple studies among diverse samples of HIV-positive drug users (Anand, Springer,
Copenhaver, & Altice, 2010; Copenhaver, Bruce, & Altice, 2008; Copenhaver, Lee,
Margolin, Bruce, & Altice, 2012; Copenhaver & Lee, 2006).
The primary aims of the parent study were to reduce sex and alcohol-related risk
behaviors associated with HIV transmission. This dissertation research sought to explore
secondary aims of the parent study — improving ART adherence and service utilization
— which were also addressed in the intervention modules.
Participants
Recruitment sites were located in densely populated, multicultural, low-income,
urban areas of South Florida, primarily Miami-Dade County, with high rates of AOD
abuse, HIV, violence and poverty. The vast majority of the participants were uninsured
with a disproportionate burden of chronic conditions associated with racial and ethnic
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health disparities. Thirteen Community-Based Organizations (CBOs) serving the target
population agreed to act as recruitment sites (see Appendix for list of sites). These CBOs
were among the largest in the local area providing outpatient AOD abuse treatment
programs and mental health services to HIV-positive men and women. Recruitment
settings were selected from a wide range of nonacademic institutions, specialty and
primary care, public and private facilities as per the National Institutes on Mental Health
(NIMH) Therapeutic Effectiveness Protocol Development Program. The agencies
providing outpatient mental health and alcohol and drug abuse treatment shared certain
attributes: Each program was designed to promote progression from preliminary
screening and biopsychosocial assessment to individually tailored addiction treatment;
each program focused on helping patients achieve and maintain abstinence from alcohol,
drugs, and sexual behaviors through case management and therapeutic activities; and the
majority of clients at these sites represented families in the lowest socioeconomic class
and received Medicaid benefits.
Intervention studies with a public health focus are designed to maximize
generalizability of findings to broad populations, providers, and settings. They have
broad sample inclusion and relatively few exclusion criteria. A total of 370 participants
meeting inclusion/exclusion criteria were recruited from the study sites between January
2009 and November 2012. The parent study was designed to maximize generalizability
of findings to broad populations, providers, and settings by including diverse subgroups
representative of “real world” settings, and minimizing exclusion criteria. The inclusion
criteria were: 1) living in Miami-Dade County; 2) being ≥18 and ≤60 years old; 3) being
HIV-positive and willing to present documentation to confirm serostatus; having
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consumed any alcohol in the past 3 months; and 4) having a history of alcohol abuse or
dependence within the past 2 years. Further criteria included: 1) facility in English; 2)
understanding of the informed consent process; 3) ability to provide contact information
to be located for more interviews; 4) willingness to be randomized to a treatment or
control group and to be contacted for follow-up assessments; 5) planning to be in the area
for the next 12 months; 6) not facing immediate incarceration or residence in a restricted
environment; and 7) currently not showing overt signs of major psychiatric disorder
including psychosis or suicidality. In addition to the parent study’s inclusion/exclusion
criteria, Aims 2 and 3 of this dissertation research also required exclusion of participants
who had not been prescribed ART. Information regarding ART prescription was
collected at baseline of the parent study.
Compensation
Participants were offered decreasing compensation: $50 gift card for a local store
upon completing the first assessment; $25 gift card for a local store upon completing
post-assessment; $15 cash or gift card for attendance at each group session; and $5 cash
for transportation.
Group Randomization
After participants completed the baseline assessment, they were entered into the
study in cohorts of eight participants of the same gender from across the recruitment
sites. Using randomized block design, cohorts were assigned to receive either the
experimental or control condition according to a computer-generated random sequence.
The random sequencing was expected to control for bias in subject assignments across
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conditions. Treatment and comparison intervention sessions were scheduled to begin
when baseline data collection was completed on a group.
To prevent cross-group contamination, each cohort group was staggered in time and
space (sessions were scheduled to take place at alternating locations). Since participants
came from different locations, there was a reduced possibility of cohorts interacting and
thus discussing their respective experiences on site.
Treatment Condition: HHRP-A
HHRP is an interactive, cognitive-behavioral group intervention that includes
components the CDC has specified as important for HIV-positive transmission risk
reduction: 1) guided by behavioral theory; 2) focused on HIV transmission risk; 3)
provided skill building and practice in coping or problem-solving skills; 4) included roleplaying safer sex communication with partners; 5) delivered in settings in which PLWH
receive services; 6) delivered in an intensive manner; and 7) including issues related to
coping with HIV status and medication adherence. HHRP-A was guided by IMB Theory
(Amico, Toro-Alfonso, & Fisher, 2005; Fisher, Fisher, Amico, & Harman, 2006; Starace,
Massa, Amico, & Fisher, 2006) and contains intervention principles similar to those of
Cognitive Behavioral Stress Management (CBSM), such as relaxation and coping skills
training designed to reduce negative mood and slow disease progression. In addition, the
group-based intervention is designed to promote interaction between participants so that
they build positive social support networks with peers. Diffusing risk-reduction
messages in peer-based social support networks may help to sustain benefits of HIV
interventions (Latkin and Knowlton, 2006).
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Group facilitators were staff similar in profile to staff at the CBO recruitment sites,
per the design of the evidence-based HHRP. Facilitators had a bachelor or high school
level education and were familiar with the study population. Participants attended eight
2-hour sessions scheduled twice a week over four consecutive weeks. The HHRP-A
therapy manual was highly structured, and involves both didactic presentation of material
and experiential exercise. Content matter was comprehensive in order to address the
medical, emotional, and spiritual needs of PLWH. Topics addressed by HHRP-A
included: 1) harm reduction skills training; 2) relapse prevention; 3) training to improve
emotional, social, and spiritual health, including coping with stigma and grief; 4)
techniques to increase medication adherence and improve participation in medical care;
and 5) strategies for making healthy lifestyle choices including reducing HIV sexual
transmission risk behavior (the original version of the intervention manual can be
accessed at http://info.med.yale.edu/psych/3s/HHRP_manual.html; fact sheet in
Appendix). Each session was co-facilitated by two trained counselors using a
nonjudgmental, motivational enhancing therapeutic style (Miller & Rollnick, 1991).
Cognitive remediation strategies were incorporated because of the potential for
cognitive impairment in this population. These strategies included: varied presentation
modalities; repetition and review; behavioral games; memory books; reduction of
distraction and fatigue; emphasis on structure and consistency; ongoing assessment of
new learning and retention, with immediate provision of feedback; and stress
management (Miller, 1993).
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Treatment Condition: Health Promotion Comparison
The proposed randomized design compared the intervention approach of HHRPA to a Health Promotion Comparison (HPC) condition. The HPC was not designed to
provide the IMB-driven techniques of HHRP-A. This condition was meant to be
educational and didactic, addressing common health problems, personal hygiene,
nutrition, physical fitness, smoking avoidance/cessation, and healthy living. HPC did not
incorporate behavioral skills training or motivational enhancement techniques and did not
promote interaction or social support network development. HPC matched HHRP- A in
total administration time and format (eight 2-hour sessions); however this modality was
condensed and delivered over a period of only two days in order to reduce the risk of
possible inflated effects in comparison group outcomes as a result of longer-term group
involvement and attention. As in HHRP-A, HPC was guided by a written manual and
implemented and held under the same conditions so as to produce equivalent expectancy
of benefit and to control for effects that could be attributed to nonspecific features of
HHRP-A.
A standard care HIV education component was included in the HPC, because it was
deemed ethically irresponsible not to include some level of HIV education in a
comparison condition, given the high-risk nature of this population. Thus, the first
session of the HPC condition included a standard care level of HIV risk reduction,
approaching what may be considered a “usual” care level that participants might expect
to receive in a typical CBO program.
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Data Collection
Several data-gathering techniques were utilized depending on the nature/content
of the instrument, and a wide range of information was covered. Assessment methods
included: 1) computer-assisted personal interview (CAPI); 2) audio computer-assisted
self-interview for subjective sensitive topics (ACASI); 3) paper and pen as specified for
neurological measures.
Measurement Instruments
The following instruments were used to measure constructs listed in the three
aims. Below is a brief description of the measurement instruments. Additional
information such as reliability and scoring is described in greater detail in the
manuscripts that follow.
Years Living with HIV(Aim 1)
Years living with HIV is a single intake questionnaire item asking the year of HIV
diagnosis. This value was subtracted from the year of intake to estimate number of years
living with HIV.
Time from HIV Diagnosis to Seeking Care (Aim 1)
Time from HIV diagnosis to seeking care is an ordinal item from the Community
Programs for Clinical Research on AIDS (CPCRA) asking “How soon after your positive
test for HIV did you first go for medical care for your HIV?” (Mannheimer, Matts,
Telzak, & Chesney, 2010). Response options included: (1) within 6 weeks; (2) 6-12
weeks; (3) 3-6 months; (4) 6-12 months; (5) more than a year; and (6) I have not gone for
medical care for my HIV.
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Alcohol and Drug Use (Aims 1 and 2)
Alcohol use, marijuana use and cocaine use were assessed using a calendar format
called time line follow-back (TLFB; Carey, Carey, Maisto, Gordon, & Weinhardt, 2001;
Weinhardt et al., 1998) to enhance accurate recall and to provide a continuous three
month history for intensity of drug and alcohol consumption. In Aim 1, these variables
were measured using three items from the TLFB: total number of “heavy drinking days”
(defined as ≥ 5 drinks), total number of marijuana use days, and total number of cocaine
use days. Aim 2 variables were measured by asking the total number of standard drinks
consumed and total number of times using marijuana in the past 3 months.
Neurocognitive Instruments (Aims 1 and 2)
The Auditory Verbal Learning Test, University of California Los Angeles/World
Health Organization Version (AVLT; Maj et al., 1994; Rey, 1964) is a test of immediate
verbal memory capacity, retrieval efficiency, and learning. Fifteen words are read to the
participant, requesting both immediate and longer-term recall. Scores for immediate
recall, delayed recall, and percent of words retained can be derived. This study utilized
the total of immediate recall scores for trials 1-5, with higher scores indicating greater
functioning.
The Color Trails Test 2, Form A (CTT2; D’Elia, 1989; D’Elia, Satz, Uchiyama, &
White, 1996; Lezak, 2004) is primarily a measure of executive functioning, but also
assesses attention, information processing, psychomotor coordination and speed. CTT-2
requires the participant to connect encircled numbers 1 through 25, randomly arranged on
a page, in proper order. CTT-2 shows all numbers twice and the participant must connect
the numbers from 1 to 25, alternating between pink and yellow circles, disregarding the
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numbers in circles of the alternate color. This analysis uses the raw time in seconds the
participant needs to complete the test, with higher scores indicating poorer functioning.
The Category Test Short Form-Booklet Format (SCT; Halstead, 1947; Wetzel,
1987) measures executive function, assessing problem-solving ability by requiring the
examinee to determine the organizing principle behind a series of visually presented
stimuli, based on the correct or incorrect external feedback from the test administrator.
This study uses the total raw error score derived, with higher scores indicating poorer
functioning.
Barriers to ART Adherence (Aim 2)
Barriers to adherence is a self-report portion of the CPCRA that includes in its
ART adherence assessment a section proposing reasons for participants’ missing any
doses of ART medication with 10 options provided; responses are dichotomous
(Mannheimer et al., 2002). Options include: “I forget to take my pills;” “I was away from
home;” and “I am too busy.”
Social Support (Aims 2 and 3)
Social support was measured using 19 items from the Medical Outcomes Study
(MOS; Sherbourne & Stewart, 1991). Questions concerned medical-related quality of life
and included four functional support scales: emotional/informational, tangible,
affectionate, and positive social interaction. Each item was rated from (1) “All of the
time” to (5) “None of the time.” For Aim 2 only four “tangible social support” subscale
items were used. This functional subscale of the MOS asks the degree to which the
participant believes s/he have available instrumental help with medical or daily living
needs. The use of subscales increases sensitivity of the instrument (Sherbourne &
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Stewart, 1991). The tangible support subscale was selected because of its strength of
association with medication adherence (Gallant & Block, 1998; Gallant, 2003; Woloshin
et al., 1993). For Aim 3, the overall social support index (total score) was used, with a
higher score indicating more support.
Stress (Aims 2 and 3)
Stress was measured with 40 items modified from the Life Experiences Survey
(LES; Sarason, Johnson, & Siegel, 1978) and the Life Events Questionnaire (Cohen et al.,
1983). The first section lists 32 events common to people in a wide variety of situations
and eight additional items address issues more specific to this population, such as their
illness and alcohol use. Items were scored on an ordinal scale based upon the degree to
which participants perceived impact of each event over the past three months. The first
32 items were two points each and the additional eight items offered three points each.
Responses to all items were summed for a total stress score (continuous measure) with
higher scores representing greater stress.
ART Adherence (Aims 2 and 3)
ART adherence was measured by the self-reported percentage of time ART
medications were taken as prescribed over the course of a week, using a portion of the
Community Programs for Clinical Research on AIDS (CPCRA; Mannheimer, Matts,
Telzak, & Chesney, 2010). The adherence score was calculated as the mean of the
combined total amount of each medication taken during the previous week, according to
the scale: “all” (100%), “most” (75%), “about half” (50%), “few” (25%), or “none” (0%)
(Mannheimer, Morse, John, & Andrews, 2006). In Aim 3, this measure was dichotomized
as < 95% and ≥ 95% average reported adherence.
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Viral Load (Aims 2 and 3)
For Aim 2, documentation of recent RNA VL (collected by participant’s own
health care provider within one month from study intake) was supplied by the participant
upon entry into the study. VL was log 10 transformed to accommodate the wide range of
values for this variable. For Aim 3, VL was a self-report measure using a single question
from the CPCRA (Mannheimer, Friedland, Matts, Child, & Chesney, 2002; McLellan et
al., 1992). Participants were asked to “Indicate your viral load the last time it was
measured” with available responses: (1) undetectable, (2) 50-500, (3) 501-5,000, (4)
5,001-10,000, (5) 10,001-30,000, (6) 30,001 or more, and (7) don’t know. Self-reported
measures of VL were significantly correlated with blood measures at baseline. This
ordinal measure was dichotomized; percent reporting an undetectable VL was reported.
Service Utilization (Aim 3)
Service utilization was assessed using a section of the Treatment Services Review
(TSR) portion of the CSAT-GPRA Client Outcome Measures for Discretionary Programs
(McLellan et al., 1992; Mclellan et al., 1989). The TSR is an intake instrument designed
for addictions treatment facilities. The section of the assessment used in this study
consists of 52 items asking whether the participant is currently or has ever received
services relevant to HIV-positive substance abusers: screening, recovery services, case
management services, medical services, after care services, education services, and peerbased recovery support services. Three additional items from the CPCRA were included:
1) “Do you receive any financial assistance to buy medications (such as ADAP, Ryan
White or other government or charitable agency)?”; 2)	
  “Is there a clinic, health center,
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doctor's office, or some other place that you usually go if you are sick or need medical
care?”; and 3) “Do you have health insurance?”
Analysis
Basic descriptive statistics were calculated and reported for all variables in the
three studies. In order to gain an understanding of the overall degree of NC impairment in
this sample, single sample t-tests were conducted to compare mean raw NC scores with
normative scores on each instrument. Norms for NC measures were obtained from
professional manuals provided for the instruments (D’Elia et al., 1996; Mitrushino,
Boone, Razan, & D’Elia, 2005; Van der Elst, van Boxtel, van Breukelen, & Jolles, 2005;
Wetzel, 1987). Proportions of participants whose scores were 1 or more standard
deviations below the norm and characteristics associated with this level of impairment
were reported.
Aims 1 and 2 were cross-sectional studies, using multivariate linear regression to
test hypothesized relationships between independent and dependent variables at a single
time point. When using linear regression for testing baseline, non-recursive models the
primary assumption is normal distribution of the data; however non-normal data can be
analyzed with the use maximum likelihood estimation (Kline, 2012). MPlus version 5.1
was used (Muthen & Muthen, 1998-2012). This software includes functions such as
robust maximum likelihood framework (MLR) and full information maximum likelihood
(FIML) to accommodate non-normality, missing data, and distributional issues of the
data (Yuan & Bentler, 2000). A limited information approach was used to obtain a rough
approximation of sample size and statistical power, accounting for at least 5% variance in
the outcome. This technique uses traditional power analysis software to gain a sense of
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sample size demands (Jaccard & Wan, 1996). Sample sizes in this study were determined
to yield a satisfactory power coefficient of > 0.95 for linear models with 10 predictors.
After addressing all diagnostic statistics, the final hypothesized structural equation model
was analyzed for its overall fit.
Aim 3 was a randomized controlled trial and analyses were conducted with SPSS
version 20. Data were assessed for random missingness (MCAR) using Little’s Missing
Completely At Random Test (Allison, 2001; Little, 1988), and continuous quantitative
missing values were imputed using the expectation maximization algorithm (Dempster,
Laird, & Rubin, 1977).	
  Change over time on continuous measures was analyzed using 2
X 3 or 4 repeated measures analyses of variance (ANOVAs) to account for treatment
condition and time variables. Data not normally distributed were square root transformed.
Where change over time in any continuous variable was detected, effect sizes (partial η2)
were reported if significant (Richardson, 2011). For the dichotomous variables, changes
between each time point were analyzed using McNemar-Bowker tests (Bowker, 1948).
Dichotomous variables were also cross-tabulated by treatment group at each time point
using chi-square analyses. Rate ratios (RRs) and 95% confidence intervals (CIs) were
presented. Significance criteria were Bonferroni-adjusted for number of analyses.
Missing categorical data were not imputed. Finally, Spearman’s rank correlation between
baseline adherence and VL at T4 was calculated as a test of veracity and accuracy of the
self-reported adherence measure (Margolin et al., 2003). Additional Spearman’s rho and
Pearson correlations between process and outcome variables, as appropriate, were
calculated.
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Theoretical Underpinnings
This three-manuscript style dissertation incorporates elements of different theoretical
health promotion models. The first manuscript tests a biomedical model. NC outcomes
are measured in context of their association with non-behavioral factors: exposure to
factors known to promote NC impairment such as living with HIV, extended time off
ART, drug use and alcohol use. The second manuscript is a baseline study utilizing a
biopsychosocial model. This study examines the direct impact of psychosocial factors
such as stress and social support on a biomedical outcome (VL) and also analyzes this
relationship through the behavioral mediator of ART adherence. The third manuscript
evaluates the effects of an intervention guided by the IMB model upon three outcomes:
ART adherence, service utilization, and VL. Variables thought to act as processes toward
the development of these outcomes are adopted from the social support stress buffering
hypothesis.
Biopsychosocial Model
George Engel posited in 1977 that humans are biological, psychological, and
social creatures who may consciously or unconsciously choose behaviors that can
promote or harm their health (Borrell-Carrio, Suchman, & Epstein, 2004; Engel, 1977).
The biopsychosocial model was adapted from the General Systems Theory (Bertalanffy,
1969), which states that all levels of an organization have linked relationships so that a
change in one level affects changes in others (Mkanta & Uphold, 2006). In a
comprehensive review of psychosomatic literature, researchers discussed key values
within the psychosomatic model, proposing that multiple psychosocial factors may
interact to promote or maintain illness and suggesting to the medical field that
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interventions utilize not only biomedical but also cognitive, behavioral, and emotional
strategies in dealing with disease (Novack et al., 2012). This holistic perspective is
important when considering the recent interest in putting ART treatment to higher use in
the prevention of HIV transmission. Not only is HIV transmission a function of
behavioral, psychological, and cognitive influences, but adherence to treatments that aim
to reduce VL are equally functions of these interacting factors.
The biopsychosocial model has been applied to many chronic diseases and several
areas of HIV research (Mkanta & Uphold, 2006). For example, Hermann et al., (2008)
suggested that the concept of ART adherence is dynamic and influenced by multiple
biopsychosocial factors in order to survey the scope and determinants of non-adherence.
Influential in social work, the biopsychosocial model is most often applied to suggest
multimodal approaches to care. For example, in linking PLWH with NC impairment to
care and services, multiple approaches — cognitive, biomedical, and psychosocial —
have been recommended (Vance & Struzick, 2007). One such approach, a therapeutic
technique called “cognitive remediation,” is an important feature of the intervention
examined in Aim 3 of this dissertation study (Miller, 1993). While the model has been
used to offer a view of service/care utilization as a combination of biologic characteristics
(e.g., genetic predisposition), psychological factors (e.g., lifestyle, stress), and social
conditions (e.g., social support) in general medicine (Jones, Edwards, & Gifford, 2002;
Rock et al., 1996), research using the model in HIV-specific care is lacking.
Information Motivation Behavioral (IMB) Model
Several models of health behavior change have been developed to better
understand the interaction of biopsychosocial factors that influence HIV transmission,
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prevention, and treatment. One theoretical framework that has effectively predicted HIV
risk and preventive behavior in diverse samples and conditions is the IMB model (Fisher
& Fisher, 1992). According to the IMB model, there are three fundamental determinants
of ART adherence: knowledge of the ART regimen and associated recommendations;
motivation to maintain ART adherence and low VL; and behavioral skills for performing
the specific adherence behaviors. This model proposes that ART adherence information
(e.g., ART regimen and side effects) and motivation (e.g., attitudes and beliefs about
adherent and non-adherent behavior), through necessary behavioral skills (e.g.,
medication self-administration and side-effects minimization), will influence adherencerelated health behaviors (Fisher, Amico, Fisher, & Harman, 2008).
Several empirical tests of the IMB model have been conducted and have
established the strength of its three major constructs in predicting ART adherence
(Amico, Toro-Alfonso, & Fisher, 2005; Starace, Massa, Amico, & Fisher, 2006).
Alternately, the model has not consistently performed in predicting adherence, with
particular weakness in defining and measuring the “motivation” construct (Amico et al.,
2009; Rongkavilit et al., 2010). Like most models designed to explain health and risk
behaviors, the IMB model requires precision in the definition of variables to be measured
(Peltzer, Friend-du Preez, Ramlagan, & Anderson, 2010).
The IMB model has been tested in a broad range of populations, including college
students (Fisher, Fisher, Williams, & Malloy, 1994), heroin injectors (Bryan, Fisher,
Fisher, & Murray, 2000), severely mentally ill adults (Kalichman, Malow, Devieux,
Stein, & Piedman, 2005), and adolescents (Kalichman et al., 2002). However, the
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constructs are likely to be most generalizable when applied to a well-defined population
(Kalichman et al., 2002).
In applying IMB to ART adherence, Fisher, Fisher, Amico & Harman (2006)
proposed a model designed to explain adherence behaviors as a function of information
and motivation operating through adherence behaviors. In their model, the outcome
behavior of adherence was actually a mediator on the path to health outcomes such as
CD4 + T-lymphocyte count and VL. This model also suggests that several moderating
factors, such as mental health and substance use, may impact health outcomes.
Buffering Hypothesis of Social Support
Although adherence and VL outcomes have been examined via the Fisher et al.,
(2008) IMB model, additional processes through which these outcomes are hypothesized
to evolve have been derived from the buffering hypothesis of social support (Cohen &
McKay, 1985). The buffering model proposes that support protects persons from the
potentially deleterious impact of stressful events. According to Cohen & McKay (1985),
an alternative model suggests that social support has a positive effect regardless of
whether a person is under stress. Evidence for this main effects model can be tested via a
statistical analysis of support with no stress × support interaction. However, this study
simply examines each variable’s independent contributions to the outcomes of a
longitudinal randomized controlled trial. Prior research examining direct impacts of
social support and the buffering hypothesis has found that both reduction of stress and
increasing social support are strongly predictive of ART adherence and service utilization
outcomes (Catz et al., 2000; DiMatteo, 2004; Gonzalez et al., 2004; Mugavero et al.,

	
  

48

2009; Simoni, Frick, Lockhart, & Liebovitz, 2002; Simoni, Frick, et al., 2006; Wong,
Sarkisian, Davis, Kinsler, & Cunningham, 2007).
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CHAPTER III
TRANSITION TO MANUSCRIPT 1
This dissertation is written in manuscript style with three publishable articles. To
adhere to word limits typically expected by journal editors, the manuscripts report only
the most essential outcomes. It is important to note additional exploration conducted in
the process of reaching the final model presented in Manuscript 1. These explorations did
not yield significant outcomes and so, while informative, were not included in the final
manuscript.
Latent variable analysis: A strategy of using the three neurocognitive (NC)
functioning variables (memory, attention and executive functioning) as indicators of one
latent variable was considered. However, limited information analyses revealed that these
variables were differentially related to other constructs in the model and this strategy was
abandoned. It was instead decided to leave the three NC factors as conceptually distinct
variables. Residual terms for these three factors were instead correlated, based upon
modifications recommended by the statistical software.
Testing for moderation: Interaction analyses were pursued to identify and
examine significant differences in the model path coefficients as a function of duration of
HIV infection (i.e., duration of HIV was considered the moderator). Product terms were
introduced into the model for all relevant paths (Jaccard & Turrisi, 2003) and included:
alcohol use x HIV exposure, marijuana use x HIV exposure, and cocaine use x HIV
exposure. Single degree of freedom interaction contrasts were performed to compare the
effects of each drug/alcohol use variable on each of the three NC variables as a function
of HIV exposure. Although statistically significant interaction contrasts were identified,
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the decision was made to not interpret these findings because there seemed to be evidence
of a suppressor effect. Specifically, the path coefficient between reported alcohol use and
memory variables was positive (greater alcohol use was associated with better memory)
among those not receiving ART.	
  Conversely, the correlation matrix revealed that these
same variables were marginally correlated in the expected direction (greater alcohol use
was associated with poorer memory). This reversal provided evidence of a possible
suppressor effect—i.e. when a moderating variable that has a zero correlation with the
dependent variable still, paradoxically, contributes to the predictive validity of the
independent variable. All product terms were excluded from the final model.
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MANUSCRIPT 1: EXPLORING FACTORS ASSOCIATED WITH
NEUROCOGNITIVE IMPAIRMENT AMONG PEOPLE LIVING WITH
HIV/AIDS
ABSTRACT
Purpose/Aims: Neurocognitive (NC) impairment continues to occur among people living
with HIV (PLWH). Alcohol and other drug (AOD) abuse may further affect NC
functioning. This study assesses the degree to which AOD use, time from HIV diagnosis
to treatment, and years living with HIV affect three areas of neurocognitive functioning
among HIV-seropositive adult alcohol abusers at a single time point.
Methods: The outcome of NC functioning in 370 PLWH living in Miami-Dade County
was assessed using: the Auditory Verbal Learning Test (AVLT; UCLA/WHO version),
the Category Test Short Format (SCT), and the Color Trails Test 2 (CTT2) which
measures several executive functions including information processing. Participants
reported the number of days using alcohol, marijuana and cocaine over the previous three
months using a calendar format. Years living with HIV infection was a single item
continuous measure and time from HIV diagnosis to seeking care was a categorical single
item measure. A Bivariate linear regression and multivariate linear regression were used
to test associations between independent and dependent variables.
Results: Mean scores on NC measures for this population were significantly lower than
mean normative scores; 39% of participants displayed NC impairment >1 standard
deviation below normative sample means on >2 NC tests. No significant associations
were found between alcohol or cocaine use and any NC measure. Marijuana use was
associated with CTT2 in the bivariate analysis (β=1.031; p=0.007). In multivariate
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analysis, each day of marijuana use and year living with HIV were associated with a .32
(p=0.05) point and 1.18 (p=0.03) point poorer performance score on the CTT2,
respectively.
Conclusion: Outcomes from this study suggest that both marijuana use and duration of
HIV infection may impair cognitive functioning among PLWH in ways that may impair
their ability to follow important treatment recommendations.
Key Words: HIV, neurocognitive, alcohol, marijuana, cocaine
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INTRODUCTION
Since the introduction of highly active antiretroviral therapy (ART), the
incidence of HIV-associated dementia has declined from 10%-15% to rates of 2%-5% of
people living with HIV (PLWH; Heaton et al., 2010; Robertson et al., 2007; Sacktor,
2002). However, milder forms of HIV-associated neurocognitive disorders (HAND) have
been reported in up to 40% of this population, in part because HIV-positive individuals
are living longer with the disease (Antinori et al., 2007; Durvasula, Norman, & Malow,
2009; McArthur, 2004; Sacktor, 2002; Sacktor et al., 2007).
HAND, ranging from asymptomatic neurocognitive impairment to profoundly
disabling HIV-associated dementia (Antinori et al., 2007), are mostly seen in advanced
stages of HIV disease but can occur even in PLWH who have medically asymptomatic
HIV infection (Grant et al., 1987; Heaton et al., 1995; White, Heaton, & Monsch, 1995).
While increased exposure to the virus, particularly during the acute phase of HIV
infection, is associated with neurocognitive (NC) impairment, HAND has been observed
to varying degrees even among PLWH who have consistently maintained low-toundetectable viral loads on ART (Simioni et al., 2010; Tozzi et al., 2007).
HAND can express clinically as impairment in episodic memory, information
processing, attention, and executive functions (Woods et al., 2009). In patients presenting
with even milder forms of HAND, quality of life can be greatly affected, with individuals
suffering from difficulties in ability to perform activities of daily living, personal health
care management, medication management and controlling risk behaviors (Hinkin et al.,
2002; Malow et al., 2012; McArthur, 2004).
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Abuse of alcohol and other drugs frequently co-occurs with HIV and may further
impair NC functioning (Substance Abuse and Mental Health Services Administration,
2011; Volkow, 2012). More than 50% of HIV-infected patients in clinic-based samples
have reported illicit drug and heavy alcohol use (Bing et al., 2001; Martin et al., 2004;
Samet et al., 2004) with marijuana and cocaine reported as the most commonly used
illicit substances among PLWH (Cook et al., 2001; Korthuis et al., 2008; Kuo et al.,
2004). Negative effects of HIV and heavy drug or alcohol use together have been
observed to affect synergistically NC functioning and the progression of HAND
(Anthony, Arango, Stephens, Simmonds, & Bell, 2007; Nath, Maragos, Avison, Schmitt,
& Berger, 2001; Rothlind et al., 2005). Among individuals with HIV infection and drug
and alcohol use disorders, impaired verbal working memory, impaired auditory working
memory, and enhanced cognitive impulsivity have been observed (Farinpour et al., 2000;
Martin et al., 2004). These cognitive functions are associated with the higher-order
thinking required to conduct safer sex practices and health management behaviors such as
ART adherence (Bryant, 2006; Hinkin et al., 2002; Meade, Conn, Skalski, & Safren,
2011; Rothlind et al., 2005).
Abuse of alcohol and other drugs has been shown to play a possible confounding
role in the assessment of NC impairment among PLWH (Justice et al., 2004). In order to
deliver targeted and effective clinical care, as well as HIV risk reduction and treatment
adherence interventions, it is important to understand specific domains of impairment
associated with exposure to HIV and the use of commonly abused substances such as
alcohol, marijuana and cocaine. By testing a biomedical model with structural equation
modeling, this study seeks to explore direct relationships between exposure to HIV and
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degree of alcohol and drug use upon several major domains of NC functioning including
memory, information processing, attention, and executive function.

METHODS
Study Design
This study employed a cross-sectional design, utilizing baseline data gathered
between 2009 and 2012 as part of a prospective randomized controlled trial for HIVpositive, adult alcohol users (R01 AA017405). Participants (N=370) were recruited from
13 community-based organizations in densely populated, multicultural, low-income areas
of Miami-Dade County, Florida with high rates of alcohol use and HIV. The inclusion
criteria were: being 18 to 60 years old; being HIV-positive; having consumed any alcohol
in the past 3 months; and having a history of alcohol abuse or dependence within the past
2 years. Further criteria included facility in English, ability to understand the informed
consent, planning to be in the area for the next 12 months, and currently not showing
overt signs of any major psychiatric disorder, including psychosis or suicidality.
Several data-gathering techniques were utilized depending on the nature and
content of the instrument being administered. Assessment methods consisted of: 1)
computer-assisted personal interview (CAPI); 2) audio computer-assisted self-interview
for subjective sensitive topics (ACASI); 3) paper and pen as specified for neurological
measures and time line follow back (TLFB).
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Measures: Independent Variables
“Years living with HIV” was measured as a single intake questionnaire item
asking the year they received their first HIV-positive test. This value was subtracted from
the year of intake to calculate number of years living with HIV.
Time from HIV diagnosis to seeking care was an ordinal item from the
Community Programs for Clinical Research on AIDS (CPCRA; Mannheimer, Matts,
Telzak, & Chesney, 2010) asking “How soon after your positive test for HIV did you first
go for medical care for your HIV?” Response options were: (1) within 6 weeks; (2) 6-12
weeks; (3) 3-6 months; (4) 6-12 months; (5) more than a year; and (6) I have not gone for
medical care for my HIV. This final response option did not provide an interval time
measurement. Two participants selecting option (6) had been diagnosed at least one year
before interview and were classified as option (5) and one participant had been diagnosed
recently so this response was coded as “missing.”
Alcohol use, marijuana use and cocaine use were assessed by TLFB using a
calendar format to enhance accurate recall and to provide a continuous three-month
history for intensity of drug and alcohol consumption. These variables were measured
using three items from the TLFB: total number of “heavy drinking days” (defined as ≥ 5
drinks), total number of marijuana use days, and total number of cocaine use days. Up to
three months’ recall of alcohol and other drug use has proved to provide reliable data
(Schroder, Carey, & Vanable, 2003). TLFB has strong agreement with other measures of
AOD use and has reliability measures ranging from 0.75 to 0.90 (Fals-Stewart, O’Farrell,
Freitas, McFarlin, & Rutigliano, 2000).
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Measures: Dependent (Outcome) Variables
A battery of three neuropsychological tests was administered to derive scores in
various cognitive domains, including memory and executive functions. These domains
were selected for importance to the parent study intervention and outcomes in this study.
For example, executive functions assess problem-solving skills and the ability to change
behavior based on external feedback, whereas information processing and memory are
related to comprehending, retaining, and applying instructions such as medical advice
and medication dosing (Lezak, 2004). The tests selected have been used in previous
studies with HIV-positive users of alcohol, marijuana and cocaine (Di Sclafani, TolouShams, Price, & Fein, 2002; Durvasula et al., 2001; Maj et al., 1994; Mason et al., 1998;
Messinis, Kyprianidou, Malefaki, & Papathanasopoulos, 2006; Rothlind et al., 2005) and
have well-developed norms, high reliability and high validity (Basso & Bornstein, 2000;
Bono et al., 1996; Selnes et al., 1997; Stern, Silva, Chaisson, & Evans, 1996). Raw NC
scores were analyzed; unadjusted NC measures provide better ecological validity when
scores are not intended to diagnose “impairment” in the sample (Silverberg & Millis,
2009).
The Auditory Verbal Learning Test, University of California Los Angeles/World
Health Organization Version (AVLT; Maj et al., 1994; Rey, 1964) measures immediate
verbal memory capacity, retrieval efficiency, and learning. Fifteen words were read to the
participant, requesting both immediate and longer-term recall. Scores for immediate
recall, delayed recall, and percent of words retained can be derived. This study utilized
the total of immediate recall scores for trials 1-5, with higher scores indicating greater
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functioning. This instrument demonstrated high test-retest reliability, with alpha scores
ranging from 0.51 to 0.72 (Lezak, 2004).
The Color Trails Test 2, Form A (CTT2; D’Elia, 1989; D’Elia, Satz, Uchiyama, &
White, 1996; Lezak, 2004) is primarily a measure of attention, cognitive flexibility,
information processing, and psychomotor speed. CTT-2 requires the participant to
connect encircled numbers 1 through 25, randomly arranged on a page, in proper order.
In addition to measuring functions of attention and information processing, this
instrument adds elements of mental flexibility and response inhibition. CTT-2 shows all
numbers twice, and the participant must connect the numbers from 1 to 25, alternating
between pink and yellow circles, disregarding the numbers in circles of the alternate
color. This analysis uses the raw time in seconds the participant needs to complete the
test, with higher scores indicating poorer functioning. The CTT-2 was developed for the
World Health Organization multicenter study of HIV infection (D’Elia, Satz, Uchiyama
& White, 1996). The test is sensitive to a variety of neurological impairments and
processes (Tombaugh, 2004) and, because it is entirely numeric and requires no language
skills, it is considered culturally unbiased (Maj et al.,1994). Additionally, the instrument
has shown strong agreement with other cognitive assessments among PLWH (Maj et al.,
1993; Maj et al.,1994) and has displayed good temporal stability with test-retest
reliability between 0.85-1.00 (D’Elia et al., 1996).
The Category Test Short Form-Booklet Format (SCT; Halstead, 1947; Wetzel,
1987) measures executive function, assessing problem-solving ability by requiring the
examinee to determine the organizing principle behind a series of visually presented
stimuli, based on the correct or incorrect external feedback from the test administrator.
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This study uses the total raw error score derived, with higher scores indicating poorer
functioning. Test-retest coefficients have varied from 0.60 to 0.96 depending upon the
severity of impairment in the sample (Wetzel L, 1987).
A hypothesized directional model was constructed to assess the degree to which
independent relationships exist between HIV exposure, alcohol use, marijuana use and
cocaine use on the outcome of NC functioning as indicated by three different cognitive
performance measures. Because advanced age is the most common predictor of
deterioration in NC functioning, analyses of duration of HIV infection were controlled
for age in the model (see below).
Analytic Strategy
Descriptive statistics were calculated for all of the variables in the model. Means,
standard deviations, skewness and kurtosis levels were calculated for all continuous
variables; frequencies were generated for dichotomous and categorical variables. In order
to gain an understanding of the overall degree of NC impairment in this sample, onesample t-tests were used to compare mean raw NC scores with normative scores on each
instrument. Raw scores were square root transformed and confidence intervals represent
the difference between the raw, transformed scores and square roots of the normative
scores. Norms for NC measures were obtained from professional manuals provided for
the instruments (D’Elia et al., 1996; Mitrushino, Boone, Razan, & D’Elia, 2005; Van der
Elst, van Boxtel, van Breukelen, & Jolles, 2005; Wetzel, 1987). Raw NC scores were
used in bivariate and multivariate regression analyses; age, gender and educational level
were entered as covariates. Bivariate regression analyses assessed relationships between
each independent and dependent variable using SPSS version 21. NC scores were square
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root transformed to adjust for non-normality for t tests and robust Maximum Likelihood
framework was invoked in MPlus version 5.1 to accommodate non-normality in the
multivariate analysis (Yuan & Bentler, 2000). Missing data bias was assessed by
computing a dummy variable reflecting the presence or absence of missing data for each
variable, which was correlated with all other variables in the model, as well as
demographic variables. No correlations between dummy variables for missing data and
all other variables in the model were statistically significant, suggesting that data were
most likely missing at random. With no systematic patterns observed in the missing data,
a full information maximum likelihood (FIML) method was used to accommodate the
missing data. A limited information approach was used to approximate sample size and
statistical power, accounting for at least 5% variance in the outcome (Jaccard & Wan,
1996). To assess non-model-based outliers, leverage indices were examined for each
participant based on their multivariate profile for the variables included in the model
analyses. An outlier was defined as an observation with a leverage score four times
greater than the mean leverage. The mean leverage score across participants was 0.09.
Based on the criteria described above, no outliers were evident in the sample data. After
addressing all diagnostic statistics, the final hypothesized model was analyzed using
Mplus software version 5.1 (Muthen & Muthen, 2008); strengths of association were
reported.

RESULTS
The mean age of participants was 44.79 years; most (63.5%) were men and
identified as black (76.2%). Most (55.7%) of participants reported at least high school
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completion; however few (8.2%) were employed. The mean number of years living with
HIV was 12.2. While most (58.4%) sought treatment within 6 weeks of receiving a
positive HIV test, 24.6% of participants waited over a year before seeking care (Table
1.1). Although not included in the tested model, the majority (76.7%) reported that they
were currently taking ART; 80% reported perfect (100%) treatment adherence; and 45%
had an undetectable viral load when last tested.
Single sample t-tests comparing the mean raw NC scores with normative scores
on each instrument showed that measures of memory, executive functioning, and
information processing for the study group were significantly poorer (all p<0.001) than
those observed in healthy samples as follows: AVLT, t=-16.25 [95% CI = -0.67, -0.52];
CTT2, t=6.65 [95% CI = 0.53, 0.97]; and SCT, t=11.52[95% CI = 0.66, 0.93]. Over a
third (39%) of the study population scored at least one standard deviation below the
mean for normative samples on at least two NC tests, consistent with clinically
significant NC impairment (Antinori et al., 2007).
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Table 1.1 (1). Sociodemographic characteristics of participants at baseline (N=370)
Mean (SD)
N (%)
44.79 (7.3)
233 (63.5%)
53 (15%)

Skewness /
Kurtosis
-0.56 / -0.13
-0.56 / -0.69
1.97 / 1.90

Black
White

266 (76.2%)
50 (14.3%)

<8th grade
Some high school
HS diploma
Some college/tech
College degree
Graduate training
Employed (Yes)
Years since HIV diagnosis
Time from HIV Diagnosis to
Treatment
Within 6 weeks
6 – 12 weeks
3 – 6 months
6 months – 1 year
1 year +
Taking ART (Yes)
Days using in last 3 mos.
Alcohol
Marijuana
Cocaine
Neurocognitive Functioning
CTT2
SCT
AVLT

29 (8.2%)
128 (36.1%)
109 (30.7%)
71 (20%)
15 (4.2%)
3 (0.8%)
29 (8.2%)
12.15 (7.5)

-1.24 / -0.47
2.05 / 2.20
0.41 / -0.17
3.07 / 7.45
0.20 / -1.01
0.65 / -1.41

Age
Gender (Male)
Hispanic Ethnicity (Yes)
Race
Years education

206 (58.4%)
13 (3.7%)
22 (6.2%)
25 (7.1%)
87 (24.6%)
273 (76.7)

-1.27 / -0.40

15.77 (23.33)
9.29 (20.68)
15.68 (23.89)

1.86 / 2.83
2.84 / 7.59
1.89 / 2.80

116.31 (49.82)*
38.09 (15.58)*
43.44 (9.63)*

1.71 / 4.97
-0.38 / -0.86
-0.03 / -0.22

* Raw scores reported. All sample means are significantly different from normative sample at p<0.01.
Normative scores used for comparison testing represented mean age and education for this sample.
Skewness and kurtosis values for neurocognitive instruments reflect distribution of scores prior to square
root transformation.

Bivariate analyses (Table 1.3) identified one significant relationship. Marijuana
use was associated with a poorer scores on the CTT2 (β=1.031; 95% CI: 0.285, 1.777;
p=0.007). After examining diagnostics for normality, outliers and patterns of missing
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data, the final model was tested. Figure 1.1 presents both significant and non-significant
path coefficients of the final model. The straight lines with arrows from observed
variables represent presumed pathways of association, and the values along the pathways
are unstandardized path coefficients. All exogenous variables were assumed to be
correlated. Unstandardized path coefficients, standard errors and 95% confidence
intervals are listed in Table 1.4. Following modification indices, it was decided to
correlate residual terms (i.e. error variance) between three measures of NC functioning.
Focused fit indices did not show evidence of Heywood cases. Standardized residual
values were <2. Focused fit indices suggested satisfactory model fit after correlating error
terms. The final model explained 8% of variance in memory, 7% of variance in
information processing, and 4% of variance in executive functions. When examining the
model, two associations approached or achieved statistical significance. On average, for
each day of marijuana use, the CTT2 score increased by 0.32, indicating poorer
performance on this NC measure. Similarly, on average, each year living with HIV
increased the CTT2 score by 1.18.
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Figure 1.1 (1). Significant regression paths among measured variables in the structural
equation model among HIV-positive alcohol abusers (N=370)

*Significant at p<0.05
Regression coefficients (represented as one-way arrows) are unstandardized.
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Table 1.2 (2). Bivariate regression statistics, 95% confidence intervals, and p-values (N=370)
Alcohol Days1
Marijuana Days2
Cocaine Days3
Years of HIV
Infection4
Time from HIV
Diagnosis to
Seeking Medical
Care5

AVLT6
CTT27
SCT8
AVLT
CTT2
SCT
AVLT
CTT2
SCT
AVLT
CTT2
SCT
AVLT
CTT2
SCT

β
-0.005
-0.137
-0.017
0.009
0.275
-0.049
0.011
-0.172
0.027
-0.075
1.031
0.096
-0.045
0.384
-0.333

1

95% CI
-0.049, .039
-0.386, 0.111
-0.089, 0.056
-0.044, 0.063
-0.024, 0.573
-0.137, 0.038
-0.032, 0.053
-0.413, 0.069
-0.033, 0.097
-0.208, 0.059
0.285, 1.777
-0.124, 0.316
-0.570, 0.480
-2.509, 3.277
-1.192, 0.526

Number of days using alcohol in past 3 months
Number of days using marijuana in past 3 months
3
Number of days using cocaine in past 3 months
4
Duration of known HIV infection in years
5
Time interval from diagnosis of HIV infection to seeking medical care.
6
Auditory Verbal Learning Test
7
Color Trails Test 2
8
Short Category Test
2
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P
0.82
0.28
0.65
0.73
0.07
0.27
0.63
0.16
0.46
0.27
0.007
0.39
0.87
0.79
0.447

Table 1.3 (3). Unstandardized path coefficients, standard errors, 95% confidence
intervals, and p-values (N=370)

Alcohol Days

1

Marijuana Days2
Cocaine Days3
Years of HIV
Infection4
Time from HIV
Diagnosis to
Seeking Medical
Care5

6

AVLT
CTT27
SCT8
AVLT
CTT2
SCT
AVLT
CTT2
SCT
AVLT
CTT2
SCT
AVLT
CTT2
SCT

Coefficient
-0.01
-0.05
0.02
0.03
0.32**
-0.01
0.00
-0.13
0.02
-0.04
1.18*
0.14
0.18
-1.77
-0.48

SE
0.03
0.16
0.04
0.04
0.17
0.06
0.03
0.14
0.05
0.10
0.54
0.15
0.38
2.33
0.61

95% CI
-0.07, 0.51
-0.36, 0.26
-0.06, 0.11
-0.05, 0.11
-0.001, 0.65
-0.13, 0.10
-0.05, 0.06
-0.40, 0.15
-0.07, 0.11
-0.23, 0.15
0.12, 2.25
-0.17, 0.44
-0.56, 0.92
-6.34, 2.79
-1.68, 0.44

P
0.79
0.75
0.59
0.45
0.05
0.82
0.94
0.37
0.65
0.66
0.03
0.37
0.63
0.45
0.43

1

Number of days using alcohol in past 3 months
Number of days using marijuana in past 3 months
3
Number of days using cocaine in past 3 months
4
Duration of known HIV infection in years
5
Time interval from diagnosis of HIV infection to seeking medical treatment.
6
Auditory Verbal Learning Test
7
Color Trails Test 2
8
Short Category Test
*Significant at p<0.05
**Approaching significance
2

DISCUSSION
This study found that NC impairment was common (39%) in this group. Other
U.S. studies of HIV-seropositive adults using similar NC measures have yielded different
results. A U.S. study of adult PLWH found their participants scored lower on CTT2 (
=100.1) than participants in this study (Ammassari et al., 2004). Another study of HIVseropositive African American men also reported significantly lower CTT2 scores with
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mean score of 93.09 for their HIV+ symptomatic group (Richardson et al., 1999). These
higher functioning levels could be explained by their samples’ lower mean age and AOD
use characteristics.
Two variables—more frequent marijuana use and prolonged duration of HIV
infection—were associated with poorer performance on one NC measure. Higher number
of days of marijuana use predicted poorer performance on the CTT2, which measured
frontal systems functioning such as attention, executive functions and information
processing (D’Elia et al., 1996; Horton Jr, 1979). Although significant differences in
CTT2 scores have been identified between HIV-positive intravenous drug users and nonusers (Starace et al., 1998), previous research on the NC effects of marijuana use has
yielded mixed results. Most studies examining marijuana-associated NC functioning
found long-term use to impede performance in domains of executive functions, verbal
memory and psychomotor speed (Bolla, Cadet, & London, 1998; Gonzalez, Carey, &
Grant, 2002; Messinis et al., 2006). While it is believed that chronic illicit drug use can
exacerbate NC sequelae of HIV infection (Anthony, Arango, Stephens, Simmonds, &
Bell, 2008; Basso & Bornstein, 2000; Norman, Basso, Kumar, & Malow, 2009), little
actual exploration of long-term cognitive impact of marijuana use has been conducted
among PLWH. One study by Cristiani, Pukay-Martin, & Bornstein (2004) reported a
significant association between marijuana use and poorer NC functioning among PLWH
with more advanced disease. These effects were most profound in the area of memory
performance.
Methodological issues associated with NC assessments and the classification of
acute versus non-acute effects of marijuana use should be considered when interpreting
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these and similar study outcomes (Gonzalez et al., 2002). In this study, a three-month
drug use history was collected with no control for any recent period of drug abstinence;
thus, marijuana use was believed to be continuous and NC performance measures may
have actually measured acute or intoxication effects of marijuana. Additionally, only
associations with performance on the CTT2 measure were significant; however, this
instrument may measure several domains of functioning, including psychomotor speed
attention (D’Elia et al., 1996). Without the corroboration of results of testing using
instruments measuring similar NC domains, the exact areas of neuropsychological impact
associated with marijuana use cannot be determined with certainty.
An additional finding of this research was that the number of years living with
HIV predicted poorer performance on the CTT2 instrument. Although the introduction
of ART has significantly reduced incidence of severe NC disorders, particularly
dementia, among PLWH, evidence of milder HAND is common even among virally
suppressed patients (McArthur et al., 2010). In this sample, no significant association was
found between NC functioning and the length of time from HIV diagnosis to seeking
care. It should also be noted that the patients evaluated in this study were heterogeneous
in ART treatment and viral suppression.
Moreover, there was a high prevalence (39%) of clinically significant NC
impairment. There are several possible explanations for the poorer NC functioning
observed to be a function of time living with HIV in this study and not necessarily as a
function of delayed ART initiation. An inflammatory response can occur when immune
functioning rebounds after treatment with ART immune reconstitution inflammatory
syndrome (IRIS). However, regardless of possible IRIS, greater immunosuppression
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remains a strong predictor of NC impairment among PLWH (Gupta et al., 2007; Heaton
et al., 2010); thus early initiation of ART is reported to be one of the most important
preventive measures against developing HAND (Müller et al., 2010; Tozzi et al., 2007).
Continuous ART adherence is also a protective factor against NC impairment (Hinkin et
al., 2002). While some participants in this study may have initiated treatment early, only
77% of participants in this group report currently taking ART. It is also possible that the
association found between years living with HIV and poorer CTT2 performance may be a
function of age-related cognitive decline (Mateen & Mills, 2012); although the analyses
were controlled for age, older age remains a strong predictor of NC impairment, and is
highly correlated with duration of HIV infection.
Certain limitations of this study are important to note. These participants were
drawn from clinical sites and may not be representative of PLWH not receiving
drug/alcohol addiction or HIV treatment. Reporting bias should also be considered in
interpreting outcomes. Nearly a quarter of the study population was in abstinence-based,
residential addiction treatment at the time of this study, and it is possible that recent
substance use was underreported, and/or that answers reflected months of abstinence in
the treatment center. Moreover, underreporting may have varied by substance; marijuana
use is likely to be less stigmatized than cocaine use (Flom et al., 2001) and possibly less
than alcohol use. Additionally, this is a cross-sectional analysis; not only is it impossible
to infer causality, but participants were heterogeneous and at different stages of care for
HIV and drug and/or alcohol treatment. Measurement issues should be considered when
interpreting this study’s results. Only three NC instruments were used; however, HIV or
drug/alcohol use can affect many other cognitive functions not evaluated here, such as
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psychomotor speed and coordination, prospective memory, and cognitive impulsivity
(Reger, Welsh, Razani, Martin, & Boone, 2002; Schuster & Gonzalez, 2012; Woods et
al., 2009). The NC instruments used were, however, commonly utilized in similar
research and considered to be reliable. Of greater concern is that poor mean NC scores
for this group may also suggest poorer recall on self-report measures.
Finally, the construct validity of some study measures should be taken into
account. As mentioned, the CTT2 may be evaluating several domains of cognitive
functioning, reducing the ability to pinpoint exact areas of impairment. In addition, the
item assessing amount of time from HIV diagnosis to seeking care did not provide
information on actual time to ART initiation. This item was intended as a measure of care
utilization; however, for the purpose of this study, the measure was used as a proxy for
ART initiation—i.e. one who sought care sooner might also be treated with ART sooner.
Counter to reports that cocaine and alcohol use exacerbate NC impairment among
PLWH (Nath, 2010), this particular study did not find such associations. Because abuse
of alcohol and illicit substances is inextricably linked to HIV (Volkow, 2012), further
investigation into interaction effects between long-term drug/alcohol use and HIV is
recommended. Further, future research should consider the contributions of substance use
to overall NC functioning for the delivery of clinical care and health behavior
interventions. Early HIV care can help decrease potential NC impairment and yield better
health outcomes for HIV-infected populations; however people suffering from substance
use disorders or cognitive impairment may find it difficult to follow important medical
recommendations (Baum et al., 2010; Braithwaite & Bryant, 2010; Bryant, 2006; Cook et
al., 2001; Hinkin, Castellon, & Durvasula, 2002; Rothlind et al., 2008). Outcomes from
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this study provide further evidence of the prevalence of NC impairment that can help to
guide and enhance interventions for PLWH who use alcohol and drugs. The delivery of
health interventions and clinical care should consider taking a harm-reduction approach:
working with the patient’s current substance use status to improve HIV treatment
adherence and service utilization and delivering interventions and services that are
sensitive to cognitive difficulties (Margolin, Avants, Warburton, & Hawkins, 2002;
Margolin et al., 2003; Miller, 1993).
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CHAPTER IV
TRANSITION TO MANUSCRIPT 2
Manuscript 2 tested a model proposing associations between psychosocial factors
on the outcome VL, mediated by ART adherence. Features of this study drew from
results found in Manuscript 1. Latent variables were not considered in the structural
equation model, so all variables were single-measure items. Cocaine was removed from
the analysis, because fewer participants reported using this drug and because no
significant associations were identified with cocaine in the first study. Although the three
NC measures did not load sufficiently to create a latent variable, they were all retained in
the analysis because each one measures unique domains of functioning.
This study used structural equation modeling to test the biopsychosocial model,
evaluating direct effects of independent and interaction variables on two dependent
variables, VL and ART adherence. A biomedical model such as that tested in manuscript
1, addresses only associations of factors known to have direct biological impact upon
health (e.g. the association of taking insulin upon blood sugar levels); whereas a
biopsychosocial model tests associations between psychological and social factors—such
as stress and social support—upon a biomarker or measurable health outcome.
Upon originally testing these relationships, interaction effects were identified
between social support and marijuana on VL and between barriers and marijuana on ART
adherence. However, after eliminating 27 non model-based outliers (9.9% of participants)
from the analysis, these interaction effects became non-significant. To assess non-modelbased outliers, leverage indices were calculated for each participant based on their
multivariate profile for the variables included in the model analyses. The leverage score
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is based on how much the observation's value on the predictor variable differs from the
mean of the predictor variable. The greater an observation's leverage, the more potential
it has to be an influential observation. A leverage score four times greater than the mean
leverage indicated presence of outliers (Jaccard & Wan, 1996). Only cases with outliers
that were statistically impossible—either due to misreporting or data entry error—were
removed. Model was analyzed with and without outliers – results were substantively the
same. However, given that outliers can bias parameter estimates the decision was made
to trim the outliers for the final model (Aguinis, Gottfredson, & Joo, 2013). The
identification of marijuana as a potential moderator should be noted for future study.
Model-based outliers were examined using limited information regression
analyses for each of the linear equations generated by the various paths included in the
model tested. Each endogenous variable was regressed onto the indicators of the
exogenous predictor variables. DfBeta is the change in the regression coefficient that
emerges after that case is deleted. An outlier was defined as an individual who had a
dfBeta three times larger than the standard error of a coefficient (> 1.0). No model-based
outliers were evident in these analyses.
In the biopsychosocial model, psychosocial factors are hypothesized to directly
affect a biomedical health outcome. Taking medication would not necessarily be included
as a mediator in this model; however, possible partial mediation by ART adherence
seemed to be an essential role to consider in a model attempting to explain VL. This
exploration was conducted because of the abundance of research supporting the
importance of ART adherence for positive health outcomes among PLWH.
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MANUSCRIPT 2: TESTING A MEDIATED BIOPSYCHOSOCIAL MODEL TO
PREDICT VIRAL LOAD AMONG PEOPLE LIVING WITH HIV
ABSTRACT
Purpose/Aims: Antiretroviral therapy (ART) adherence is associated with improved
HIV-related health outcomes, whereas inadequate treatment adherence predicts increased
mortality, viral replication, and increased risk of transmitting the virus to others.
Neurocognitive (NC) impairment, drug and alcohol abuse, and psychosocial factors such
as stress all have been associated with poorer adherence, while social support has
predicted better adherence rates. This study sought to explore the degree to which stress,
social support and ART adherence barriers impact viral load (VL) via ART adherence
among HIV-seropositive adults.
Methods: This study used multivariate linear regression modeling using Mplus to test a
mediated biopsychosocial model predicting VL among a cross-sectional sample of 246
HIV-positive adults who were on ART. Exogenous variables were tangible social
support, barriers to ART adherence, and stress. Moderators were alcohol use, marijuana
use and NC impairment. The mediator was ART adherence. Baron and Kenny’s four-step
approach was used to test mediation.
Results: A small positive association between marijuana use and adherence approached
significance (β=0.15, p=0.057). Each additional barrier predicted a 10% decrease in
adherence rates and a 0.42-unit increase in log10 VL. No interaction effects were
identified. The relationship between barriers to adherence and log10VL was partially
mediated by ART adherence.
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Discussion: These findings provide modest support for the biopsychosocial model in
predicting virologic response to ART. Outcomes may provide a more complete picture of
the complex factors affecting the lives of HIV-positive adults. A holistic perspective
should be considered when providing health care or delivering interventions aimed at
improving ART adherence and health outcomes.
Key Words: HIV, biopsychosocial, viral load, adherence
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INTRODUCTION
Over 600,000 people in the United States have died from complications related to
infection with HIV since the beginning of the epidemic (Centers for Disease Control and
Prevention, 2013). Dramatic decreases in HIV-related death rates since the mid-1990s
are due to the introduction of highly active antiretroviral therapy (ART; Centers for
Disease Control and Prevention Division of HIV/AIDS, 2012). Optimal adherence to
ART can stop viral replication, rendering viral levels undetectable in both blood and
sexual fluids and reducing risk of HIV transmission (Lima et al., 2011; Volkow, 2012).
ART adherence improves health outcomes by promoting ART’s effectiveness in
suppressing viral replication and restoring immune function and is believed to be central
to successful treatment (Bangsberg et al., 2000; Carpenter et al., 1997; Deeks et al., 1997;
Descamps & Flandre, 2000; Katzenstein, 1997; Paterson et al., 2000). Inadequate
treatment adherence is associated with increased mortality, viral replication, and
increased risk of transmitting HIV to others (Bangsberg, Perry, Charlebois, et al., 2001;
Quinn et al., 2000).
Several psychosocial factors, including social support, are known to have a direct
impact on ART adherence (Amico & Orrell, 2013; Diiorio et al., 2009; DiMatteo, 2004;
Safren et al., 2001; Simoni, Frick, et al., 2006). Studies have shown that psychosocial
factors may also directly improve virologic response and slow HIV disease progression
(Ironson & Hayward, 2008); however, results are mixed. Social support may be the most
frequently tested predictor of HIV-related health outcomes. Several studies have found
significant positive associations between support and immunologic response or HIV
symptoms (Ashton et al., 2005; Solano et al., 1993; Theorell et al., 1995). Other research
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has not found a direct relationship between social support and either biomarkers
(Ironson, O’Cleirigh, et al., 2005) or clinical evidence of HIV disease progression (Luigi
Solano et al., 2002; Thornton et al., 2000), although these studies show more evidence of
effects of various psychosocial factors on clinical and immunologic disease progression
than directly on VL. In addition, other psychosocial factors associated with HIV
medication management such as conscientiousness and proactive coping have been found
to positively impact ART adherence (Ironson, Balbin, et al., 2005; O’Cleirigh, Ironson,
Weiss, & Costa, 2007). However, no prior studies have explored links between these
psychosocial constructs and virologic response to ART, controlled for ART adherence.
People living with HIV/AIDS (PLWH), particularly from low-income or
disadvantaged populations, may be exposed to a range of life stressors that could inhibit
treatment adherence (Mugavero et al., 2009; Wong et al., 2007). Stressful life events and
trauma have not only been linked with poorer health behaviors but may also be associated
with lower CD4 count, higher viral load (VL), and more rapid disease progression
(Ironson, O’Cleirigh, et al., 2005; Leserman, 2008; Leserman et al., 2007; Mugavero et
al., 2013). Psychosocial factors such as stressful life events have also been found to affect
health biomarkers such as CD4 count and VL via neural/endocrine mediation of stressrelated hormones such as cortisol and norepinephrine (Cole, 2008).
Supporting Engel’s (Engel, 1977) biopsychosocial model, the field of
psychosomatic medicine has proposed that multiple psychological and social factors may
promote or maintain illness, suggesting that interventions should consider not only
biological intervention (i.e. surgery and medicine) but also cognitive, behavioral, and
emotional strategies in dealing with disease (Novack et al., 2012). The medical model,
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accounting only for factors with a direct biological association to health outcomes, has
reigned as the predominant paradigm of health and disease, however it is becoming more
commonly accepted that illness and wellness are the result of an interaction between
biological, psychological and social factors (Leigh & Reiser, 1985; Matarazzo, Weiss,
Herd, & Miller, 1984; Sarafino, 1994).
This holistic perspective of health and disease is important to consider, especially
with recent efforts to increase the role of ART in the prevention of HIV transmission.
For example, Hermann et al. (2008) suggested in their research that the concept of ART
adherence is dynamic, influenced by multiple biopsychosocial factors. While correlates
of ART adherence have been studied extensively, there remains a gap in research
examining relationships of common biopsychosocial factors and their influence on
biomarkers such as VL. ART adherence is certainly of great importance in HIV disease
management and prevention, but adherence alone is useless without related
improvement in the biomarkers that measure immune function and viremia.
When examining the effects of psychosocial predictors on health behaviors and
outcomes, cognitive and behavioral factors believed to moderate these relationships are
important to consider. Many PLWH are affected by neurocognitive (NC) impairment and
drug or alcohol abuse. Mild forms of HIV-associated NC disorders (HAND) continue to
be observed in up to 40% of PLWH (Durvasula et al., 2009; Sacktor et al., 2002, 2007;
Tozzi et al., 2007) and such impairment can hinder ART adherence (Hinkin et al., 2002).
Studies have identified specific domains of functioning — such as verbal memory
and executive functioning — associated with deficiencies in optimal ART adherence
(Applebaum, Reilly, et al., 2009; Hinkin & Hardy, 2004; Waldrop-Valverde et al., 2006;
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Wright et al., 2011). There is substantive evidence of the link between alcohol and
general illicit drug use and ART non-adherence (Bryant et al., 2010; Lucas et al., 2006;
Samet et al., 2004), but research regarding adherence and marijuana use in particular is
mixed (Corless et al., 2009; de Jong et al., 2005; Prentiss et al., 2004; Tucker et al.,
2003). Further, research concerning marijuana use, and its potential effects upon
virologic, immunologic and other health markers among PLWH, is limited.

METHODS
Sample
This study sought to test a biopsychosocial model as described above, predicting
VL, mediated by ART adherence. Internal (constant) independent variables were age,
education and gender. External independent variables were social support, stress and
barriers to treatment adherence, moderated by cognitive and behavioral factors (NC
impairment, alcohol use and marijuana use). Cross-sectional data was gathered between
2009 and 2012 at baseline of a prospective randomized controlled trial for HIV-positive,
adult alcohol-users. Participants were recruited from 13 community-based organizations
in urban, low income areas of Miami, Florida. The inclusion criteria were: being ≥18 and
≤60 years old; being HIV-positive; having consumed any alcohol in the past 3 months;
and having a history of alcohol abuse or dependence within the past 2 years. Further
criteria included facility in English, planning to be in the area for the next 12 months,
understanding the informed consent, and currently not displaying overt signs of major
psychiatric disorder including psychosis or suicidality. An additional inclusion criterion
for this study was self-report of current prescription of ART. Of the 370 participants
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recruited, 77% (N=273) had been prescribed ART and were eligible for this study. After
removing 27 model-based outliers, 246 participants were evaluated.
Measures
Several data-gathering techniques were utilized depending on the nature and
content of the instrument being administered. Assessment methods included: 1)
computer-assisted personal interview (CAPI); 2) Audio computer-assisted self-interview
(ACASI) for subjective sensitive topics; 3) paper and pen as specified for neurological
measures and a calendar format; and 4) timeline follow-back (TLFB; Carey, Carey,
Maisto, Gordon, & Weinhardt, 2001; Weinhardt et al., 1998) which enhances recall and
provides a continuous three month history to assess intensity of drug and alcohol
consumption.
ART adherence data consisted of self-reported percentage of time ART
medications were taken as prescribed over the course of a week, per the Community
Programs for Clinical Research on AIDS (CPCRA; Mannheimer, Matts, Telzak, &
Chesney, 2010). The adherence score was calculated as the mean of the combined total
amount of each medication taken during the previous week, according to the scale: “all”
(100%), “most” (75%), “about half” (50%), “few” (25%), or “none” (0%) (Mannheimer,
Morse, John, & Andrews, 2006). The CPCRA has shown significant correlation with
other self-report instruments (Wang et al., 2008) and has effectively predicted biologic
outcomes (Mannheimer, Friedland, Matts, Child, & Chesney, 2002). Documentation of
recent RNA viral load (collected by the participant’s own health care provider) was
supplied by the participant upon entry into the study. Lab measures must have been
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collected one month before or after the date of baseline assessment. VL was log10transformed for analysis.
Tangible social support was measured using four items from the Medical
Outcomes Study (MOS; Sherbourne & Stewart, 1991). This functional subscale of the
19-item social support measure measures the degree to which the participant has
instrumental help with medical or daily living needs. Each item is rated from (1) “none of
the time” to (5) “all of the time.” A higher score indicates greater tangible support. The
use of subscales increases sensitivity of the instrument (Sherbourne & Stewart, 1991).
The tangible support subscale was selected because of its strength in predicting health
outcomes and medication adherence (Gallant & Block, 1998; Gallant, 2003; Woloshin et
al., 1993). The MOS had strong internal consistency with a Cronbach’s alpha of 0.96 for
the full instrument and 0.89 for the tangible support subscale. All subscales have shown
strong reliability over time (alphas > 0.91) and the four tangible support subscale items
have high convergent validity with scale items correlating from 0.72 to 0.87 (Sherbourne
& Stewart, 1991).
Stress was measured with 40 items modified from the Life Experiences Survey
(LES; Sarason, Johnson, & Siegel, 1978). The first section lists 32 potentially stressful
events common to people in a wide variety of situations and eight additional items
address issues more specific to this population, such as their illness and alcohol use.
Items were scored on a Likert scale based upon the degree to which participants’
perceived impact of each event over the previous three months. The first 32 items were
scored with two possible points each and the additional 8 items were scored with three
possible points each. Higher scores indicated higher potentially stressful impact.
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Responses to all items were summed for a total stress score. Reliability for this measure
was strong for this sample with a Cronbach’s alpha calculated at 0.95.
Barriers to adherence is a self-report portion of the CPCRA that offers ten
possible reasons for missing any doses of antiretroviral medication with dichotomous
(yes/no) responses (Mannheimer et al., 2002). Options include: “I forget to take my
pills”; “I was away from home”; and “I am too busy.” Internal consistency of items was
0.81.
A battery of three neuropsychological tests was administered to derive scores in a
range of cognitive domains including memory, information processing, and executive
functions. The tests selected have been used in previous studies with PLWH who use
alcohol and other drugs, and these tests have well-developed norms and high reliability
and validity (Basso & Bornstein, 2000; Bono et al., 1996; Selnes et al., 1997; Stern et al.,
1996). The Auditory Verbal Learning Test, University of California Los Angeles/World
Health Organization Version (AVLT; Maj et al., 1994; Rey, 1964) measures immediate
verbal memory capacity, retrieval efficiency, and learning. Fifteen words were read to the
participant, requesting both immediate and longer-term recall. Scores for immediate
recall, delayed recall, and percent of words retained can be derived. This study utilized
the total of immediate recall scores for trials 1-5, with higher scores indicating greater
functioning. This instrument demonstrated high test-retest reliability, with alpha scores
ranging from 0.51 to 0.72 (Lezak, 2004). The Color Trails Test 2, Form A (CTT2;
D’Elia, 1989; D’Elia, Satz, Uchiyama, & White, 1996; Lezak, 2004) is primarily a
measure of executive functioning but also assesses attention, information processing,
psychomotor coordination and speed. CTT-2 requires the participant to connect encircled
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numbers 1 through 25, randomly arranged on a page, in proper order. In addition to
measuring functions of attention and information processing, this instrument adds
elements of mental flexibility and response inhibition. CTT-2 shows all numbers twice,
and the participant must connect the numbers from 1 to 25, alternating between pink and
yellow circles, disregarding the numbers in circles of the alternate color. This analysis
uses the raw time in seconds the participant needs to complete the test, with higher scores
indicating poorer functioning. The CTT-2 was developed for the World Health
Organization multicenter study of HIV infection (D’Elia, Satz, Uchiyama & White,
1996). The test is sensitive to a variety of neurological impairments and processes
(Tombaugh, 2004) and, because it is entirely numeric and requires no language skills, it
is considered culturally unbiased (Maj et al.,1994). Additionally, the instrument has
shown strong agreement with other cognitive assessments among PLWH (Maj et al.,
1993; Maj et al.,1994) and has displayed good temporal stability with test-retest
reliability between 0.85-1.00 (D’Elia et al., 1996). The Category Test Short FormBooklet Format (SCT; Halstead, 1947; Wetzel, 1987) measures executive function,
assessing problem-solving ability by requiring the examinee to determine the organizing
principle behind a series of visually presented stimuli, based on the correct or incorrect
external feedback from the test administrator. This study uses the total raw error score
derived, with higher scores indicating poorer functioning. Test-retest coefficients have
varied from 0.60 to 0.96 depending upon the severity of impairment in the sample
(Wetzel L, 1987).
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Raw NC scores were analyzed; unadjusted NC measures are known to provide
better ecological validity when scores are not intended to diagnose impairment in the
sample (Silverberg & Millis, 2009b). Scores on this battery were dichotomized.
Participants who scored at least one standard deviation below normative means on at
least two instruments were identified as displaying greater NC impairment (Antinori et
al., 2007). Normative data for CTT2 and AVLT were obtained from professional manuals
provided for the instruments (D’Elia et al., 1996; Van der Elst et al., 2005; Wetzel &
Boll, 1987). Norms for AVLT were retrieved from The Handbook of Normative Data for
Neuropsychological Assessment (Mitrushina et al., 2005). Comparison groups were
assumed to be healthy, uninfected populations.
Recent alcohol and marijuana use were assessed by TLFB (Carey et al., 2001;
Weinhardt et al., 1998; Weinhardt, Otto-Salaj, Brondino, Norberg, & Kalichman, 2002),
using a calendar format to enhance accurate recall and to provide a continuous history of
drug and alcohol consumption. These two variables were measured by asking the total
number of drinks consumed and total number of times using marijuana in the past three
months. Up to three months recall of alcohol and other drug use has proven to provide
reliable data (Schroder et al., 2003). An analysis of test-retest reliability yielded intraclass
correlations ranging from 0.70 to 0.94 in a drug-using sample (Fals-Stewart et al., 2000).
Analytic Strategy
Descriptive statistics and skewness/kurtosis values were calculated for all of the
variables in the model. Means and standard distributions were calculated for all
continuous variables; percentages were provided for categorical and ordinal variables.
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Missing data bias was evaluated by computing a dummy variable that reflected
the presence or absence of missing data for each variable. A full information maximum
likelihood (FIML) method was used to accommodate the missing data. Robust Maximum
Likelihood framework accommodated issues of data distribution (Yuan & Bentler, 2000).
A limited information approach provided approximate sample size and statistical power,
accounting for at least 5% of variance in the outcome (Jaccard & Wan, 1996). To assess
non-model-based outliers, leverage indices were examined for each participant based on
his/her multivariate profile for the variables included in the model analyses. A leverage
score four times greater than the mean leverage indicated presence of outliers. Only
outlier cases that were uninterpretable and significantly impossible were eliminated from
final model analysis (N=27). Model-based were defined as a participant with an absolute
standardized DfBeta coefficient > 1.0 and none were detected based upon this criterion.
Moderation analysis first requires the creation of product terms between each
independent variable and each moderator, which represented the interaction effect (Aiken
& West, 1991; Jaccard, Turrisi, & Wan, 1990). All predictor variables were centered to
protect against multicollinearity.
After addressing all diagnostic statistics, the final hypothesized multivariate linear
regression model was analyzed using the Mplus software version 5.1 (Muthen & Muthen,
2008). Non-significant product terms were sequentially dropped from the model until
only significant ones remained. The SEM approach tested a linear moderated model such
that Y = b0 + b1X1 + b2X2 + b3X1X2 + e. Fit indices, path values and confidence intervals
were reported.
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Interaction effects and mediation were analyzed separately (Fairchild &
Mackinnon, 2009; Ryu, West, & Sousa, 2009). After confirming that all variables
considered for a mediation model were correlated, mediation was tested in four
traditional steps (Baron & Kenny, 1986; James & Brett, 1984; Judd & Kenny, 1981):
Step 1 was to test associations between independent variables and the mediator. Step 2
was to test associations between independent and dependent variables. Step 3 was to test
the relationship between the mediator and dependent variables. Step 4 was to regress the
independent variables on the dependent variables, controlling for the mediator to assess
whether the association between independent and dependent variables persisted. Linear
regression for testing mediation was conducted using SPSS version 20 (IBM, 2011). In
addition, a Sobel Test was conducted to confirm mediation using the Sobel online
calculator (Sobel, 1982).

RESULTS
The mean age of participants was 45 years; 66% were male, 77.3% reported their
race as black and 13.5% reported their ethnicity as Hispanic (Table 2.1). Most (55.9%)
participants reported at least high school graduation, but few (9%) were employed. Mean
self-reported ART adherence over a one-week period was 93.5%, with 81.5% of
participants reporting adherence of ≥ 95%. VL ranged from undetectable to over 900,000
copies per mL with a mean VL of 16,246 (64,685); 28% had <50 copies/mL. NC
impairment was observed in 34 of participants. Mean scores on all three NC measures
were significantly lower than mean scores healthy, uninfected norms (Table 2.2).
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Table 2.1 (1). Sociodemographic characteristics of participants and descriptive
statistics of variables in the model (N=246)
	
  

Mean (SD) / N (%)

Black
White

187 (77.3%)
36 (14.9%)

<8th grade
Some high school
High school graduate
Some college/tech
College degree
Graduate training
Employed (Yes)

19 (7.8%)
89 (36.3%)
70 (28.6%)
53 (21.6%)
11 (4.5%)
3 (1.2%)
22 (8.9%)

Skewness/
Kurtosis
-0.58 / -0.05
-0.68 / -1.55
0.44/ -0.18
-

93.5 (19.96)
16,948 (64,685)
69 (28%)
13.30 (4.85)
47.85 (34.46)
165 (89.2%)
173 (261.18)
19.17 (34.77)
84 (34.1%)

-3.59/ 12.83
7.06 / 58.27
-0.23 / -0.74
-0.33 / -0.88
3.37 / 11.30
3.18/ 12.02
1.62 / 1.11
0.54 -1.71

Age
Gender (Male)
Hispanic ethnicity (Yes)
Race
Years education

45.24 (7.04)
161 (66%)
33 (13.5%)

ART adherence (percent)1
VL
VL (undetectable)
Social Support (MOS)
Stress (LES)
Barriers to adherence (zero)
Alcohol (# drinks/90 days)
Marijuana (# times using/90 days)
NC impairment (Yes)
1

Median adherence = 100%

Table 2.2 (2). Neurocognitive scores for participants and healthy norms (N=246)
	
  

NC Instrument
CTT2
SCT
AVLT

Raw Score (SD)
129.14 (53.72)*
36.65 (15.58)*
43.13 (9.44)*

*significant at p<0.001
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Norms
96.35 (29.57)
27.35 (12.1)
51.1 (8.6)

The sample size (246) accounted for at least 5% of unique variance in the
outcome, modeling for multiple regression analysis with 11 predictors, squared multiple
correlation of 0.10 (the lowest observed in the modeling) and a 0.05 alpha level, yielding
a satisfactory power coefficient of 0.98. The mean leverage score across participants was
0.139, and 27 outliers were identified based upon the leverage score criterion described
above. None of the correlations to assess missing data bias were statistically significant,
indicating that data were missing at random. After examining data for distribution issues,
outliers and patterns of missing data, the final moderated model was tested (Figure 2.1),
presenting both significant and non-significant path coefficients of the final model with
non-significant product terms removed. The straight lines with arrows from observed
variables represent presumed pathways of association and the values along the pathways
are unstandardized path coefficients—expressed in terms of actual scores. All exogenous
variables were assumed to be correlated. Unstandardized path coefficients, standard
errors and 95% confidence intervals are listed in Table 2.3. The final model was just
identified and no fit indices are reported.
The final model explained 31% of variance in ART adherence and 18% of
variance in log10 VL. When examining associations between predictors and outcomes,
two significant paths were identified. Each increase in number of barriers to adherence
predicted a 10.06% decrease in adherence to ART and also predicted a 0.42 unit increase
in log10 VL. No interaction effects were identified.
A modest association between marijuana use and ART adherence was observed
and approached significance (β=0.15, p=0.057); however the variable “barriers to
medication adherence” was the only independent variable significantly associated with
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both ART adherence and VL in the SEM, so this was the only variable considered for
further testing in a mediated relationship. Barriers, ART adherence and VL were
significantly correlated (Table 2.4).
Linear regression results for mediation testing are reported in Table 2.5. Step 1:
“Barriers” was significantly negatively associated with adherence (β=-9.47; p < 0.001).
Step 2: “Barriers” was significantly associated with higher VL (β= 0.30; p=0.002). Step
3: Adherence was associated with lower VL (β=-0.02; p=0.05). Step 4: “Barriers” ceased
to be associated with VL when controlling for adherence (β=0.20; p=0.09). This suggests
that mediation was not full, as confirmed by the Sobel Test (β=0.99, p=0.32) but much of
the effect of “barriers to adherence” on VL was apparently due to their effect on ART
adherence.
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Figure 2.2 (2). Regression paths among measured variables in the structural
equation model among HIV-positive alcohol abusers (N=246)

*P<0.05
Regression coefficients (represented as one-way arrows) are unstandardized.

Table 2.3 (3). Unstandardized path coefficients, standard errors, 95% confidence intervals
and p-values (N=246)
Support
Stress
Barriers to
Adherence
NC1Impairment
Marijuana
Alcohol
Age
Education
Gender
1

	
  

NC Neurocognitive

Adherence
VL
Adherence
VL
Adherence
VL
Adherence
VL
Adherence
VL
Adherence
VL
Adherence
VL
Adherence
VL
Adherence
VL

Coefficient
0.56
0.02
-0.002
-0.002
-10.06
0.42
2.09
-0.25
0.15
0.01
0.02
0.00
0.19
0.02
1.51
-0.15
3.63
0.20
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SE
0.41
0.13
0.05
0.004
1.72
0.13
2.29
0.26
0.08
0.01
0.07
0.01
0.19
0.02
1.52
0.11
2.91
0.29

95% CI
-0.49, 1.60
-0.05, 0.08
-0.13, 0.13
-0.01, 0.01
-14.49, -5.63
0.08, 0.75
-3.81, 7.99
-0.91, 0.41
-0.05, 0.34
-0.01, 0.02
-0.18, 0.21
-0.02, 0.02
-0.30, 0.69
-0.04, 0.07
-2.40, 5.42
-0.44, 0.13
-3.86, 11.11
-0.45, 0.85

P
0.17
0.54
0.97
0.57
<0.001
0.001
0.36
0.33
0.06
0.14
0.84
0.95
0.31
0.44
0.32
0.16
0.21
0.49

	
  

Table 2.4 (4). Correlation matrix for all variables in the model (N=246)
1.Adhere
2. VL
3.Support
4. Stress
5. Barriers
6. NC.Impairment
7. Alcohol
8. Marijuana
9. Age
10. Gender
11. Education
*Significant at p<0.01

1
1.00
-0.26*
0.15
0.04
-0.50*
0.06
0.01
0.11
0.08
0.06
0.01

2

3

4

5

6

7

8

9

10

1.00
-0.01
-0.06
0.36*
-0.08
0.01
0.10
0.01
0.08
-0.06

1.00
0.02
-0.07
0.00
-0.07
-0.04
-0.16
-0.13
-0.03

1.00
0.02
0.14
-0.06
-0.04
-0.07
-0.13
-0.17

1.00
-0.01
0.00
0.04
0.06
0.15
-0.01

1.00
0.08
0.00
0.14
0.03
-0.11

1.00
-0.04
0.02
0.08
-0.04

1.00
0.18
0.10
-0.02

1.00
-0.04
0.00

1.00
0.06

Table 2.5 (5). Linear regressions, test for mediation (N=246)
1

Barriers =>Adherence
Barriers =>VL
ART Adherence=>VL
Barriers (control for Adherence) =>VL
Adherence (control for Barriers) =>VL
1.
Barriers to ART Adherence
Sobel p=0.32

Unstd. β
-9.47
0.30
-0.02
0.21
-0.01

SE
1.03
0.10
0.01
0.01
0.01

95% CI
-11.50, -7.43
0.11, 0.49
-0.03, -0.003
-0.03, 0.01
-0.03, 0.009

P
0.00
0.002
0.02
0.09
0.29

R2
0.35
0.08
0.05
0.1
0.1

DISCUSSION
Results from this study provide modest support for a biopsychosocial approach to
understanding the HIV-related health outcome studied, specifically, virologic
suppression. The biopsychosocial model suggests that psychosocial, cognitive and
behavioral factors may directly influence a biomedical outcome (Engel, 1977). This
model has been successfully applied to disease processes and causes (Alonso, 2004;
Matarazzo & Leckliter, 1988) but less successfully applied to health outcomes. When
used to examine health outcomes, the biopsychoscial model is most often applied to

	
  

107

disease symptoms such as pain (Jones et al., 2002; McLean, Clauw, Abelson, &
Liberzon, 2005), and biomarkers of chronic disease (blood pressure, blood sugar) or
gastrointestinal illnesses (Drossman, 1998). In HIV infection, a considerable body of
evidence suggests that stressors may adversely affect biomarkers of disease progression,
particularly CD4 count and mortality (Ironson & Hayward, 2008). Unlike VL, these
health outcomes have been clearly linked to the stress-response system, also termed the
hypothalamo-pituitary-adrenal (HPA) axis. In a comprehensive review of empirical
studies, Cole (2008) suggested that sympathetic nervous system and HPA axis mediation
may exist between psychosocial factors and HIV pathogenesis, that is, how HIV causes
illness, particularly immunosuppression. Less support exists for a direct link between
HPA axis function and VL.
In this study, the only psychosocial variable found to be significantly associated
with VL was barriers to adherence to ART. Although it is a measure of perceived
barriers, this construct may be a proxy for ART adherence itself. Hence, this study
provides only modest support for the application of a biopsychosocial model predicting
VL among PLWH. The relationship between number of barriers and actual adherence
rates has been observed in other studies (Catz et al., 2000). However, no such studies
were identified that include VL as a health outcome. The present study suggests,
however, that ART adherence does not mediate fully the relationship between perceived
barriers and VL. Were adherence to mediate fully the relationship between barriers and
VL, no direct influence of the psychosocial predictor on the biomedical outcome could be
supported.

	
  

108

Identifying direct links between psychosocial factors and HIV biomarkers has
proved challenging. Thornton et al., (2000) conducted a longitudinal analysis of CD4
count and time to AIDS diagnosis, predicted by stressful life events and social support.
Neither was found to be significantly associated with these outcomes. In addition, a metaanalysis conducted by Zorilla, et al. similarly found no psychosocial predictors of HIV
progression (Zorrilla, McKay, Luborsky, & Schmidt, 1996). Finally, Solano et al., (1993)
reported several psychosocial variables associated with disease progression in PLWH
with poorer immune functioning, although these were not strong predictors for those
with higher CD4 counts.
Multiple studies have revealed effects of stress or social support on HIV
biomarkers or other indicators of disease progression (Ashton et al., 2005; Ironson &
Hayward, 2008; Ironson, O’Cleirigh, et al., 2005; Leserman, 2008; Mugavero et al.,
2013; Theorell et al., 1995). None of the studies describing such effects after the
introduction of ART investigated the possibility of ART adherence acting as a mediating
variable. As reported for a biopsychosocial model exploring the effects of stress, stability
and treatment adherence on insulin-dependent diabetes (Peyrot, Mcmurry, & Kruger,
2013), medication adherence (ART adherence in the case of this study) is essential in
chronic disease management to achieve optimal health outcomes.
Alcohol abuse has been shown to result in deleterious physical outcomes
including poor adherence to health care recommendations, particularly for following a
medication regimen (Bryant, 2006; Cook et al., 2001; Samet et al., 2004), however this
study did not identify such associations. On the contrary, a modest positive association
between marijuana use and ART adherence approached statistical significance in this
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study. Although research has found marijuana use to decrease ART adherence (Tucker et
al., 2003), some studies suggest that marijuana use may serve to reduce symptoms and
improve ART adherence among PLWH (de Jong et al., 2005). It is possible that different
degrees of use or dependence may play a role in whether this drug serves to improve or
hinder ART adherence (Bonn-Miller, Oser, Bucossi, & Trafton, 2012).
Certain limitations of this study should be noted when interpreting results. First,
participants were recruited from clinical sites, reducing generalizability to non-clinical
samples. Also, about one-third of the sample was in residential drug or alcohol treatment
at the time data were collected, and reporting bias may exist particularly for responses to
questions about drug and alcohol use. The fact that many participants were engaged in
care may also account for the unusually high adherence rates reported in this sample.
High adherence rates may also be explained by the use of self-report measurement which
has been found to provide inflated values (Cramer, Mattson, Prevey, Scheyer, &
Ouellette, 2013; Waterhouse, 1993). Finally, findings reported are based on a crosssectional analysis. In examining mediation, Maxwell and Cole (2007) note that estimates
using cross-sectional data may be biased (as compared with longitudinal data) because of
the failure to allow for autoregressive effects of the mediator and outcome variables.
Baron and Kenny (1986), Holland (2013), and MacKinnon (2007) caution that without a
randomized experiment one cannot rule out possible alternative explanations accounting
for significant associations identified.
Findings from this study suggest that viral suppression among PLWH is largely a
product of ART adherence, with a modest direct effect of psychosocial factors. Since
ART adherence remains the primary predictor of virologic suppression and improved
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health outcomes among PLWH, fostering adequate medication management must remain
a priority for the HIV care community. However, ART adherence rates are subject to
fluctuations based upon stress, social support, NC impairment and drug and alcohol use.
Thus, maintaining a holistic perspective of health care and regard for the myriad
psychosocial factors in the lives of PLWH can improve health outcomes. It is important
to assess broader, more ecological models for determining health outcomes such as viral
load when a biomedical approach alone has failed to eradicate HIV progression and
transmission. Findings from this study may help shed light on psychosocial factors
associated with HIV-related health and illness that are responsive to intervention.
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CHAPTER V
TRANSITION TO MANUSCRIPT 3
Following is the final manuscript of this dissertation. This study evaluates the
effectiveness of an evidence-based intervention on improving antiretroviral treatment
adherence, increasing service utilization and reducing viral load among people living
with HIV. Although Manuscripts 1 and 2 also examined data gathered in the same parent
study, this study is prospective, utilizing data before and up to six months after the
delivery of the intervention. Hence, the study population size is smaller than those of the
former studies because of attrition: of the 337 participants assigned to cohorts at baseline,
211 were available to complete assessments at 6 months post-intervention.
Outcomes from the prior two cross-sectional manuscripts helped contribute to the
conceptualization of this set of analyses. For example, Manuscript 1 provided
information about the overall neurocognitive functioning for this sample, which helped
explain how this intervention’s cognitive remediation strategies may have aided in
positive health behavior outcomes. In Manuscript 2 no association was found between
tangible social support and ART adherence, so in this study the general social support
scale was utilized. Although “barriers to adherence” was a significant predictor of
adherence in Aim 2 of this dissertation, it was not central to the theoretical model for the
following study and was therefore dropped.
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MANUSCRIPT 3: EFFECTIVENESS OF AN EVIDENCE-BASED
INTERVENTION IN IMPROVING TREATMENT ADHERENCE, SERVICE
UTILIZATION AND VIRAL LOAD AMONG HIV-SEROPOSITIVE ADULT
ALCOHOL USERS
ABSTRACT
Background: Up to 95% adherence to antiretroviral therapy (ART) may be necessary to
sustain viral suppression and reduce risk of HIV transmission; however, achieving high
levels of adherence may be challenging for people who abuse alcohol or suffer from
neurocognitive impairment. This study evaluated whether a manual-guided intervention
significantly improved ART adherence, service utilization and VL among HIV-positive
adults with a history of alcohol abuse.
Methods: A total of 243 HIV-seropositive adults, recruited from community based
organizations in South Florida were randomized to the Holistic Health Recovery Program
(HHRP-A) or a comparison condition. Both groups attended eight sessions and provided
self-reported data on outcomes, including adherence, service utilization, and viral load
(VL), and on processes, including social support and stress. Data were collected at
baseline, immediately post-intervention, 3-month, and 6-month follow-up time points.
Results: Participants were ≥18 and ≤60 ( =45.7 years old), 74% male, and 78% black.
Participants randomized to the HHRP-A condition were significantly more likely to
report adequate ART adherence and to report an undetectable VL at 6 months postintervention. An effect was also observed on social support, with participants in the
HHRP-A condition showing significantly greater improvement than the comparison
group.
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Discussion: Findings suggest that providing comprehensive health promotion
interventions, particularly those incorporating cognitive remediation strategies, could
greatly improve self-reported health outcomes for HIV-seropositive substance users.
Key Words: HIV, alcohol, adherence, intervention, addiction
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INTRODUCTION
Since the mid-1990s, antiretroviral therapy (ART) has successfully extended the
lives of people living with HIV/AIDS (PLWH; Centers for Disease Control and
Prevention Division of HIV/AIDS, 2012a, 2012b; Palella et al., 1998). Thus, the goal of
HIV care has shifted toward achieving long-term optimal health outcomes through
consistent treatment. Adequate adherence to ART improves health outcomes and is
critical for successful disease management; conversely, inadequate treatment adherence is
associated with increased morbidity and mortality, viral resistance, limited future
treatment options and increased risk of HIV transmission to others (Bangsberg, Perry, &
Charlebois, 2001; Bangsberg et al., 2000; Carpenter et al., 1997; Deeks, Smith, Holodniy,
& Kahn, 1997; Paterson et al., 2000; Volkow & Montaner, 2010). As much as 95%
adherence may be necessary to achieve positive clinical outcomes. However, achieving
the level of adherence necessary to suppress viral replication can be challenging, with
recent studies reporting that anywhere between 18% and 73% of PLWH are non-adherent
to antiretroviral therapy (Bangsberg, Moss, & Deeks, 2004; Catz, Kelly, Bogart,
Benotsch, & Mcauliffe, 2000; Lucas, 2005; Paterson et al., 2000; Tesoriero et al., 2003).
These adherence levels may be even lower for PLWH experiencing alcohol
abuse or neurocognitive impairment [NCI] (Baum et al., 2010; Braithwaite & Bryant,
2010; Bryant, 2006; Cook et al., 2001; Hinkin, Castellon, & Durvasula, 2002; Rothlind et
al., 2008), both of which are commonly comorbid with HIV. Alcohol abuse has been
reported by up to 53% of adults with HIV (Galvan et al., 2002; Heaton et al., 2010) and
NCI ranging from asymptomatic neurocognitive impairment (ANI) to HIV-associated
dementia (HAD) has been observed in about 37% of adult PLWH (Sacktor, 2002). Heavy
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alcohol use and NCI may have a negative synergistic effect on self-reported medication
adherence and service utilization rates (Bass et al., 2012; Marx, Malka, Ravishankar, &
Schwartz, 2011; Rothlind et al., 2005). Improving utilization of both HIV and substance
abuse services is central to increasing treatment adherence and optimizing health
outcomes for PLWH (Mugavero et al., 2009, 2013; White House Office of National
AIDS Policy, 2010). Through adequate and consistent care, patients are better able to
receive the support necessary to achieve adequate treatment adherence, sustain optimal
health outcomes, and, ultimately, help to reduce the incidence of HIV. Hence, there
remains a pressing need to continue developing, adapting, and testing evidence-based
interventions aimed at improving service and care utilization and improving health
behaviors such as ART adherence.
One theoretical framework that has effectively predicted HIV-related health
behaviors in diverse samples is the Information-Motivation-Behavioral Skills (IMB)
model (Fisher & Fisher, 1992). Several empirical tests of this model have established the
strength of its three major constructs in predicting ART adherence and service utilization
(Amico et al., 2005; Margolin et al., 2003; Smith, Fisher, Cunningham, & Amico, 2012;
Starace et al., 2006). An adaptation of the IMB model proposed by Fisher et al. (2008)
posits that ART treatment-related information and motivation to be adherent will operate
through necessary behavioral skills to influence adherence-related health behaviors
(Fisher, Amico, Fisher, & Harman, 2008). To benefit from an IMB-guided intervention,
participants are expected to possess the cognitive capacity to process and translate
intentions into health behaviors. These capacities may be diminished among HIV-
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seropositive adults with a history of alcohol abuse (e.g., Farinpour et al., 2000), thus
impeding their abilities to benefit from a therapeutic intervention.
This study evaluated the effectiveness of an IMB-based, manual-guided
intervention on improving outcomes of viral load (VL), ART adherence and service
utilization among PLWH with a history of alcohol abuse. While this intervention was
geared primarily toward reducing sex and drug/alcohol risk behaviors, service utilization,
ART adherence and virologic response were secondary aims of the intervention. Process
variables associated with the development of these outcomes were derived from the
Fisher et al. (2008) IMB adherence model and the buffering model of social support
(Cohen & McKay, 1985). Prior research applying these models have found that both
stress reduction and increasing social support are strongly predictive of ART adherence
and service utilization outcomes (Catz et al., 2000; DiMatteo, 2004; Gonzalez et al.,
2004; Mugavero et al., 2009; Simoni et al., 2002; Simoni, Frick, et al., 2006; Wong et al.,
2007).
Using recommended methodologies for testing manual-guided interventions
(Hirokazu, Wilson, Peterson, & Shinn, 2005), a randomized	
  clinical trial was conducted
to determine whether a manual-guided risk reduction intervention produced lower VL
and greater antiretroviral treatment adherence and service utilization outcomes over and
above a standard-of-care, health promotion comparison group. The delivery of a group
intervention that included cognitive remediation strategies and addressed this
population’s unique needs was expected to facilitate learning and retention of risk
reduction behavioral skills central to achieving these outcomes. In addition, the study
sought to assess whether a reduction of stress and an increase in social support was
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achieved and if these factors provided any additional contribution to achieving the
intended outcomes.

METHODS
Participants
A total of 370 HIV-seropositive, alcohol-using adults were recruited from
community-based organizations (CBOs) in Miami, Florida between January 2009 and
November 2012. A slower recruitment period was planned to help prevent against
treatment group contamination and group assignment bias. The inclusion criteria were:
being 18-60 years old; documented HIV infection; having consumed any alcohol in the
past 3 months; having a history of alcohol abuse or dependence within the past 2 years;
displaying facility in English; ability to understand the informed consent; ability to be
located for follow-up over the course of a year; willingness to be randomized to a
treatment or control group; and currently not showing overt signs of major psychiatric
disorder including psychosis or suicidality. An additional inclusion criterion for this study
was self-report of current prescription of ART.
After participants completed the baseline assessment, they were entered into the
study in cohorts of eight participants of the same gender. Cohorts were assigned to
receive either the experimental or control condition according to a computer-generated
random sequence. The random sequencing was expected to control for bias in subject
assignments across conditions.	
  Assessment methods included: CAPI (computer assisted
personal interview); ACASI (audio computer assisted self-interview) for subjective
sensitive topics; and paper and pen as specified for neurological measures. Data were
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collected at baseline (T1), immediately post-intervention (T2), 3 month follow-up (T3),
and 6 month follow-up (T4) for all measures; however, no adherence or stress data were
collected at T2.
The research protocol was approved by the Institutional Review Board of Florida
International University, and all participants provided signed informed consent prior to
participating in the study. Participants were offered decremental monetary compensation:
$50 gift cards to local stores upon completing the first assessment; $25 gift card upon
completing post-assessments; $15 cash or gift card for attendance at each group session;
and $5 cash for transportation.
Outcome measures
ART adherence was defined as the self-reported percentage of time ART
medications were taken as prescribed over the course of a week. The Community
Programs for Clinical Research on AIDS (Mannheimer, Matts, Telzak, & Chesney, 2010)
assesses whether the individual has accurately taken all doses of the medications. For
each antiretroviral medication taken, participants rated their adherence according to the
scale: “all” (100%), “most” (75%), “about half” (50%), “few” (25%), or “none” (0%); the
mean adherence for all medications was calculated (Mannheimer, Morse, John, &
Andrews, 2006). Perfect adherence was defined as greater than 95%. While definitions of
adherence have varied greatly in the literature, this cutoff was set to compare with the
level established by Margolin (2003). Self-reported adherence was significantly
correlated with serum VL at baseline (rs=-0.33, p=0.02).
Service utilization was assessed using a section of the Treatment Services Review
(TSR) portion of the CSAT-GPRA Client Outcome Measures for Discretionary Programs
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(McLellan et al., 1992; Mclellan et al., 1989). The TSR is an instrument designed to
collect intake data at addictions treatment facilities. The section of the assessment used in
this study asked the participant “Are you currently or ever received any of the following
Treatment Service?” The 52 services listed are relevant to HIV-positive substance
abusers, including screening, recovery, case management, medical, after care, education,
and peer-based recovery support services. Three additional items from the CPCRA were
included: 1) “Do you receive any financial assistance to buy medications (such as ADAP,
Ryan White or other government or charitable agency?”); 2)	
  “Is there a clinic, health
center, doctor's office, or some other place that you usually go if you are sick or need
medical care?”; and 3) “Do you have health insurance?” The TSR has high test-retest
reliability, concurrent validity in differentiating between levels of care (McLellan et al.,
1992), and a Cronbach’s alpha of 0.93 at baseline of this study.
Viral load (VL) was a self-report measure using a single question from the
CPCRA (Mannheimer, Friedland, Matts, Child, & Chesney, 2002; McLellan et al., 1992).
Participants were asked to “Indicate your viral load the last time it was measured” with
available responses: 1) undetectable, 2) 50-500, 3) 501-5,000, 4) 5,001-10,000, 5)
10,001-30,000, 6) 30,001 or more, 7) don’t know. Self-reported VL measures were
significantly correlated with blood measures at baseline (rs=-0.21, p=0.03). Percent
reporting an undetectable VL was reported.
Process measures
Social support was measured using all 19 items from the Medical Outcomes
Study (MOS; Sherbourne & Stewart, 1991). Questions concerned medical conditionrelated quality of life and comprised of four functional support scales:
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emotional/informational, tangible, affectionate, and positive social interaction. Each item
is rated from (1) “all of the time” to (5) “none of the time.” The overall social support
index (total score) was used, with a higher score indicating more support. The MOS was
developed for patients involved in a 2-year study investigating chronic conditions. All
subscales have shown strong reliability over time (alphas > 0.91). For this study sample
the Cronbach’s alpha was 0.96.
Stress was measured with 40 items modified from the Life Experiences Survey
(Sarason, Johnson, & Siegel, 1978) and the Perceived Stress Scale (Cohen et al., 1983)
developed by the Semel Institute-Neuropsychiatric Institute (NPI) of the University of
California, Los Angeles (available at http://chipts.ucla.edu/wpcontent/uploads/downloads/2012/02/Life-Events.pdf). The first section is a list of 32
events common to people in a wide variety of situations such as divorce, moving, and
loss. If a participant indicated that an event occurred in the past three months, s/he rated
it: (1) “very bad,” (2) “somewhat bad,” (3) “somewhat good,” and (4) “very good.” Items
rated (1) or (2) were reverse scored and summed for a negative impact score. Items rated
3 or 4 were not counted (Sarason, et al., 1978). Eight additional items listed issues more
specific to PLWH, such as their illness and alcohol use and rated on the degree to which
each issue bothered them from (1) “not at all” to (5) “extremely.” Items scored (3), (4),
or (5) were recoded from 1-3 respectively and added to the negative impact score for a
total of 88 possible points. Reliability for this measure was strong for this group with a
Cronbach’s alpha calculated at 0.95.
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Treatment conditions
Experimental Condition (n=127, 52.3%)
The evidence-based intervention evaluated was an adapted version of the Holistic Health
Recovery Program (HHRP-A) which has been translated to manual format for in detail
uniform implementation (Margolin et al., 2003), and disseminated by the CDC’s
Diffusion of Effective Behavioral Intervention (DEBI) program
(www.effectiveinterventions.org) program. Some HHRP-A core elements include
teaching: decision-making and problem solving skills using cognitive remediation
strategies; goal-setting skills, including developing action plans; skills to manage stress,
including relaxation exercises and understanding what aspects of the stressful situation
can, and cannot, be controlled; skills to improve health, healthcare participation, and
adherence to medical treatments; skills to increase clients' access to their own selfdefined spiritual beliefs, in order to increase motivation to engage in harm reduction
behaviors; and skills to increase awareness of how different senses of self can affect selfefficacy and hopelessness. In addition, the group-based intervention is designed to
promote interaction between participants so that they build positive social support
networks with peers. Diffusing risk-reduction messages in peer-based social support
networks may help to sustain benefits of HIV interventions (Latkin and Knowlton, 2006).
Per the design of the evidence-based HHRP, group facilitators were staff similar
in profile to those of the CBO recruitment sites in that they had a high school-to-bachelor
level education and were familiar with urban Miami-Dade County. Participants attended
eight 2-hour sessions scheduled 1 to 2 times per week over consecutive weeks conducted
from February 2009 through December, 2012. The HHRP therapy manual
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(http://info.med.yale.edu/psych/3s/HHRP_manual.html) was highly structured, and
involves both didactic presentation of material as well as experiential exercises. Content
matter was comprehensive in order to address the medical, emotional, and spiritual needs
of individuals living with HIV. Topics addressed by HHRP-A included: stress reduction,
harm reduction skills training; relapse prevention; improving emotional, social, and
spiritual health, including coping with stigma and grief; increasing medication adherence;
improving participation in medical care; and making healthy lifestyle choices, including
reducing HIV sexual transmission risk behavior. Each session was co-facilitated by two
counselors using a nonjudgmental, motivational enhancing therapeutic style (Miller &
Rollnick, 1991).
Cognitive remediation strategies (Miller, 1993) were incorporated because of the
potential for NCI in this population. These strategies included: varied presentation
modalities; repetition and review; behavioral games; memory books; reduction of
distraction and fatigue; emphasis on structure and consistency; ongoing assessment of
new learning and retention, with immediate provision of feedback, and stress
management.
Comparison Condition (n=116, 47.7%)
The randomized design compared the experimental treatment to a Health
Promotion Comparison (HPC) condition. The HPC was not designed to provide the IMBdriven techniques of HHRP-A. This condition was meant to be educational and didactic,
addressing common health problems, personal hygiene, nutrition, physical fitness,
smoking avoidance/cessation, and healthy living. HPC did not incorporate behavioral
skills training or motivational enhancement techniques and did not promote interaction or
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social support network development. HPC matched HHRP-A in total administration time
and format (eight 2-hour sessions); however this modality was condensed and delivered
over a period of only two days in order to reduce the risk of possible inflated effects in
comparison group outcomes as a result of longer-term group involvement and attention.
As in HHRP-A, HPC was guided by a written manual, implemented, and held
under the same conditions so as to produce equivalent facilitator attention and expectancy
of benefit and to control for effects that could be attributed to nonspecific features of
HHRP-A.
A standard care HIV education component was included in the HPC as it was
deemed ethically responsible to include some HIV education in a comparison condition,
given the high-risk nature of this population. Thus, one session of the HPC condition
delivered a standard care level of HIV risk reduction, simulating what may be considered
a “usual” care level that participants might expect to receive in a typical CBO program.
To prevent cross-group contamination, each cohort group was staggered in time and
space (sessions were scheduled to take place at alternating locations). Since participants
came from different locations, there was a reduced possibility of cohorts interacting and
thus discussing their respective experiences on site. Finally, study coordinators estimated
that any inadvertent exchange of information between HHRP-A and HPC members
would be more likely to reduce the differences between the two groups than bias the
results to inflate Type 1 errors.
Analysis
Analyses were conducted with SPSS version 20 (IBM, 2011). Continuous
measures were service utilization, stress and social support. Data were assessed for
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random missingness (MCAR) using Little’s Missing Completely At Random Test
(Allison, 2001; Little, 1988) and continuous quantitative missing values were imputed
using the expectation maximization algorithm (Dempster et al., 1977). The three
continuous variables were square root transformed for analysis due to moderate nonnormal distribution (Tabachnick and Fidell, 2007; Howell, 2007). Change over time on
continuous measures was analyzed using 2 X 3 or 4 repeated measures analyses of
variance (ANOVAs) to account for treatment condition and time variables. Where change
over time in any continuous variable was detected, effect sizes (partial η2) were reported
if statistically significant (Richardson, 2011).
For the dichotomous variables, VL (detectable or undetectable) and adherence
(>95% versus lower), changes between each time point were analyzed using McNemarBowker tests (Bowker, 1948). Dichotomous variables were also cross-tabulated by
treatment group at each time point using chi-square analyses. Rate (prevalence) ratios
(RRs) and 95% confidence intervals (CIs) are presented. Significance criteria were
Bonferroni-adjusted for number of analyses. Missing categorical data were not imputed.
Controlling for VL at baseline, Spearman’s rank correlation between baseline
adherence and VL at T4 was calculated as a partial test of veracity and accuracy of the
self-reported adherence measure (Margolin et al., 2003), implicitly assuming absence of
significant resistance to the antiretrovirals prescribed. Additional Spearman’s rho and
Pearson correlations (as appropriate) were calculated between process and outcome
variables.
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RESULTS
Socio-demographics
All consecutively recruited PLWH were screened for eligibility; 337 of the
eligible participants met all requirements for randomization and the 243 who reported
receiving ART at all time points were included in this study. Table 1 presents
sociodemographic, HIV, and NC descriptive characteristics of the participants at baseline
prior to randomization. The final sample for the intervention was 70.8% male and had a
mean age of 45 (SD=6.9) years. Nearly 80% identified as African American and 12.2%
as White. Fourteen percent considered themselves to be of Hispanic ethnicity. A total of
55% had at least a high school diploma and 9% were employed. At entry into the study,
participants provided recent (within one month from intake) lab tests of CD4 count and
VL; means were 440 and 11,588 copies/ml, respectively with 26% showing an
undetectable viral load. A large proportion of participants displayed a degree of NCI;
38.7% scored at least one standard deviation below the mean for normative samples on at
least two neuropsychological tests sensitive to a range of cognitive capacities (Antinori et
al., 2007).
	
  

Table 3.1 (1). Descriptive characteristics of all randomized sample at baseline

Age
Gender
Education

	
  

HHRP-A
N=127
Mean (SD)
N (%)
45.71 (6.3)

HPC
N=116
Mean (SD)
N (%)
44.68 (7.5)

TOTAL
N=243
Mean (SD)
N(%)
45.22 (6.90)

Male
Female

93 (74%)
32 (26%)

77 (67%)
38 (33%)

170 (71%)
70 (29%)

<8th Grade
Some HS, not graduate a
HS graduate or GED

9 (7%)
45 (37%)
32 (26%)

10 (9%)
40 (36%)
34 (31%)

19 (8%)
85 (37%)
66 (29%)
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Hispanic Ethnicity
Race

Some college
College degree
Any graduate training

26 (22%)
7 (5.8%)
2 (2%)
16 (13%)

19 (17%)
6 (6%)
1 (1%)
17 (16%)

45 (19%)
13 (6%)
3 (1%)
33 (14%)

Black
White

92 (78%)
17 (15%)
9 (7%)
12.89 (6.92)
449 (218)
10,870 (22,159)
25 (20%)

87 (80%)
11 (10%)
12 (11%)
13.55 (7.53)
430 (240)
13,411 (73,158)
38 (33%)

179 (79.6%)
28 (12.4%)
21 (9%)
13.20 (7.23)
440 (228)
12,083 (52,921)
63 (26%)

43.78 (9.04)
37.23 (15.92)
119.63 (50.40)

43.46 (9.75)
39.95 (12.93)
114.25 (55.04)

43.62 (9.35)
38.53 (14.60)
117.06 (52.62)

Employed (Yes)
Years living with HIV
CD4 count (copies/ml)
Plasma Viral Load (copies/ml)1
Viral Load (<50 copies/mL)
Neurocognitive functioning (raw scores)
Auditory Verbal Learning Test
Short Category Test (trials 1-5)
Color Trails Test 2
1

Median VL=2,460 for all participants	
  

Receipt of intended level of treatment and retention
Group participants agreed to be videotaped and rated for counselor competence
and observance of the implementation manual (Carroll, Kadden, Donovan, Zweben, &
Rounsaville, 1994). There were no significant differences in adherence, service
utilization, or VL measures by treatment group assignment at baseline. Of the 243
randomized participants, 87% completed at least 6 out of 8 intervention sessions; 63%
were available at the 6-month follow up to complete the survey instruments (Figure 3.1)
and those completing 6 month assessments did not differ significantly by group
assignment However, session completion varied significantly by study assignment, with
84/127 (66.1%) of eligible participants assigned to the treatment condition completing >6
sessions, versus 104/116 (89.7%) of comparison group participants (t=4.95; p<0.001).
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Figure 3.1 (1). Number of participants enrolled at each time point (N=243)

	
  

*Number of sessions attended was significantly different between groups (t=4.95, p<0.001)
Proportion who completed all sessions was significantly different between groups (χ =46.70, p<0.001)
2

	
  

Outcomes
Of all participants who reported being on ART throughout the study (N=243), the
following proportions reported better than 95% adherence: 83% at baseline, 89.3% at T3
and 86.6% at T4 (Table 3.2). Changes in reported adherence across time points were not
statistically significant. Chi square analyses (Table 3.3) showed a significant difference
(RR=1.55; 95% CI: 1.09, 2.18; p=0.049) between treatment groups in the proportions of
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participants reporting >95% adherence at T4 (HPC=80.6% versus HHRP-A=90.3%). No
differences in adherence or VL between conditions observed at other time points
approached statistical significance. Self-reported adherence at baseline was significantly
correlated with VL at 6 months when controlling for VL at baseline (rs=-0.310, p<0.01).
The mean number of services utilized (out of possible 52) by all participants at
baseline was 17.62 (SD=10.11) which decreased at T2 to 11.89 (SD=8.53), increased at
T3 to 16.08 (SD=9.76), and decreased again at T4 to 14.38 (SD=8.60). A significant
change in utilization was observed over time regardless of treatment condition [F (3,
645)=19.07, p<0.001; partial η2 =0.073]. No time x condition interaction or betweengroup difference in utilization were observed (Table 3.4).
Upon entry into the study, 103 (55.1%) participants reported their VL to be
undetectable with no significant difference in VL between treatment conditions. Change
in percentages of those reporting an undetectable VL between baseline (T1) and T2, T3
or T4 was not significant: 56.8% at T2, 66.0% at T3, and 66.1% at T4. As shown in Table
3.3, at the 6-month follow-up, participants assigned to the HHRP-A group were more
likely (74.6%; RR=1.49; 95% CI: 1.05, 2.13) to report an undetectable VL than those
assigned to the HPC condition (56.7%, p<0.01).
Processes
Participants at baseline, regardless of group assignment, reported a mean support
score of 67.98 (SD=17.61) out of a possible score of 95. A significant change in scores
over time for both HPC and HHRP-A groups was observed, with mean scores increasing
at T2 to 70.36 (+14.98), at T3 to 70.90 (+15.25) and at T4 to 70.46 (+14.04) [F=4.19,
p<0.01, partial η2 =0.02]. The interaction between time point and condition approached
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significance [F=2.37, p<0.06, partial η2 =0.01] whereby the experimental condition
performed significantly better over time than the comparison group. No between-groups
effect was observed when time points were collapsed.
Stress measures were collected at baseline, T3 and T4. Participants regardless of
condition assignment had a mean stress score of 26.87(SD=17.10) at baseline. The scores
decreased to 25.99 (SD=15.55) at T3 and increased to 26.37 (SD=14.45) at T4.
Differences in overall scores over time were not significant. No time x condition or
between-groups effects were observed (Table 3.4).
One significant correlation was identified between process and outcome variables:
at 6 month follow-up for participants in the HHRP-A condition, adherence was positively
associated with support (r=0.28, p<0.05; Table 3.5).
	
  
Table 3.2 (2). Outcome and process values (N/% and Mean/SD) at all available time points
(N=243)

Adherence
>95%
Utilization

Undetectable
VL
Stress

Support

	
  

HPC
HHRP-A
All
HPC
HHRP-A
All
HPC
HHRP-A
All
HPC
HHRP-A
All
HPC
HHRP-A
All

T1
Mean (SD)
N (%)
64/79 (81.0%)
63/74(85.1%)
127/153 (83.0%)
17.62 (10.11)
16.20 (9.58)
16.88 (9.85)
51/91 (56.0%)
52/96 (54.2%)
103/187 (55.1%)
27.36 (17.86)
26.41 (16.44)
26.87 (17.10)
68.89 (17.80)
67.14 (17.47)
67.98 (17.61)

T2
Mean (SD)
N (%)
12.55 (8.88)
11.28 (8.19)
11.89 (8.53)
50/82 (61.0%)
42/80 (52.5%)
92/162 (56.8%)
71.37 (13.90)
69.44 (15.90)
70.36 (14.98)
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T3
Mean (SD)
N (%)
67/74 (90.5%)
58/66 (87.9%)
125/140 (89.3%)
15.79 (9.61)
16.35 (9.93)
16.08 (9.76)
44/71 (62.0%)
55/79 (69.6%)
99/150 (66.0%)
26.61 (16.54)
28.31 (16.19)
27.49 (16.34)
70.40 (15.77)
71.37(14.81)
70.90 (15.25)

T4
Mean (SD)
N (%)
50/62 (80.6%)
53/57 (93%)
103/119 (86.6%)
14.74 (9.48)
14.05 (7.74)
14.38 (8.60)
34/60 (56.7%)
50/67 (74.6%)
84/127 (66.1%)
25.99 (15.55)
26.72 (13.42)
26.37 (14.45)
69.20 (14.52)
71.61(13.53)
70.46 (14.04)

Table 3.3 (3). Rate ratios for 95% ART adherence and undetectable viral load, by study
assignment (N=243)

SelfReported
Adherence
SelfReported
Undetectable
VL

T1
x
Condition
1.15
0.96

-

T2
x
Condition
-

5.52

0.84

T1-T2

1.69

T3
x
Condition
0.87

6.08

1.19

T1-T3

0.97

T4
x
Condition
1.55*

2.49

1.49**

T1-T4

* p=0.049
** p=0.033

Table 3.4 (4). Effects (F statistics) for continuous variables by time and study assignment
(N=243)
Time (p)
Time x Condition (p)
Utilization
19.07 (p<.001)
0.37 (p=0.75)
(df: 3, 645)
Stress
0.46 (p=0.61)
0.98 (p=0.37)
(df: 2, 440)
Support
4.19 (p=0.01)
2.36 (p=0.06)
(df: 3, 687)
*Derived from Greenhouse-Geisser statistics
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Between Groups (p)
0.30 (p=0.58)
0.45 (p=0.50)
0.01 (p=0.92)

Table 3.5 (5). Pearson and Spearman Rank correlations between outcome and process
variables at baseline, post-intervention, 3 months, and 6 months (N=243)

SelfReported
Adherence
Service
Utilization

T1
T3
T4
T1
T2
T3
T4
SelfT1
Reported
T2
VL
T3
T4
*significant at p<0.05

HPC
-.07
.06
.19
0.04
0.03
0.02
0.002
0.11
0.06

Stress

HHRP-A
.09
.19
-.09
0.05
0.04
-0.13
0.10
0.11
0.00

HPC
-0.22
-0.05
0.09
0.06
0.16
0.10
0.08
0.04
0.20
0.15
-0.08

Support

HHRP-A
0.06
-0.05
0.28*
0.00
0.16
-0.14
0.07
0.14
0.13
-0.05
-0.11

DISCUSSION
Participants enrolled in this study were at high risk of disease progression and
reported risk behaviors associated with HIV transmission (Malow et al., 2012). Many
reported less-than-optimal ART adherence, and most reported a detectable viral load and
clinically significant NCI. The study group showed significantly lower NC functioning
when compared to published norms. This study found that the HHRP-A group showed
improved VL and adherence at 6 months post intervention. In addition, social support
improved throughout follow up and was significantly associated with adherence at 6
months post intervention.
The evidence-based intervention evaluated in this study improved self-reported
ART adherence in HIV-positive adults who used alcohol, more than the HPC at the sixmonth follow-up time point, but not at other time points post-intervention. Other IMB
model-based interventions, particularly those that employ strategies to facilitate learning
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and retention, have yielded similar outcomes. Margolin et al. (2003) found success in
improving self-reported adherence rates among methadone-maintained injection drug
users after delivery of an adapted HHRP intervention. Another study developed an IMBbased health literacy training which showed some effectiveness in improving adherence
among a heterogeneous sample of HIV-positive adults (Ownby, Waldrop-Valverde,
Caballero, & Jacobs, 2013). Similar to the research presented here, both of those
intervention studies involved PLWH who were engaged in clinical care, adherence rates
were high at the outset and “adequate adherence” was set at 95%. Ownby found the
greatest improvement among participants who began at the lowest levels of adherence;
however that study did not include a comparison condition. Additionally, neither of the
previous interventions studies examined prospective outcomes. Finally, although the
accuracy and veracity of self-report adherence measures vary greatly in the literature
(Simoni, Kurth, et al., 2006), the fact that adherence values at baseline in this study were
significantly correlated with VL at 6 months suggest high accuracy in adherence
reporting.
While improvement in ART adherence is a promising outcome, undetectable VL
should be the ultimate marker of health improvement. Uncontrolled viral replication and
associated immune activity can result in a chronic inflammatory state, organ damage and
other conditions, including NC impairment (Thompson et al., 2012). In this study,
significantly more participants in the HHRP-A condition reported an undetectable VL six
months, but not at other time points after the intervention. A recent meta analysis
examining associations between both self-reported and directly observed ART adherence
and VL suggested that longer term analysis, such as the 6-month time frame used in this
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study, yields stronger associations (Kahana, Rohan, Allison, Frazier, & Drotar, 2013).
Also, an incrementally larger proportion of the sample in the experimental condition
reported an undetectable VL at each follow-up time point, but this improvement was not
statistically significant. The magnitude of association between these variables is often due
to methodological factors, particularly using a dichotomous measure of VL (Kahana et
al., 2013). Hence, a continuous measure of VL could have provided different outcomes in
this study.
Although this study did not employ a mediated model, an attempt was made,
nonetheless, to explore possible mechanisms through which improvements in outcomes
may have operated. Effectiveness of the intervention in improving social support and
reducing stress were mixed. The intervention included numerous stress-reduction and
relaxation activities; however perceptions of life stress appeared to be unaffected by the
intervention, in contrast to trials delivering similar cognitive-behavioral techniques,
which have resulted in better stress outcomes (Antoni et al., 1991; Lopez et al., 2011).
Social support, on the other hand, improved significantly as a function of both time and
treatment condition. Between baseline and post-intervention, participants’ participation in
either group may have provided a greater perception of support (Lutgendorf et al., 1998).
However, support scores for the HPC condition declined after T2, while participants in
the HHRP-A group continued to report increased social support throughout the study
period. This longitudinal difference in social support between the two conditions could
have been due to the difference in format of the two intervention groups; HHRP-A met
over a longer period of time.
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The study did not completely support the buffering model of social support.
Although at 6-month follow-up, report of >95% adherence among participants
randomized to the HHRP-A condition was positively correlated with social support,
adherence was not correlated with stress at this time point. The relationship between
social support, stress and adherence has been repeatedly supported in the literature (Catz
et al., 2000; Gonzalez et al., 2004; Paterson et al., 2000; Singh et al., 1999), however the
use of more focused indicators of support, particularly instrumental or adherence-specific
support scales, could yield stronger associations with health behavior outcomes
(DiMatteo, 2004; Lehavot et al., 2011; Simoni, Frick, et al., 2006).
Contrary to one of this study’s hypotheses, a significant reduction in reported
service utilization was observed for all participants in the months following the
intervention. This finding may be explained by changes in residential status during this
study: nearly a quarter of the sample was in residential drug or alcohol treatment at
baseline, dropping to under 5% in residential treatment at follow up time points. As
reported in prior studies, a change in structured inpatient support is likely to have
disrupted participants’ access to services (Arno et al., 1996; Kim, Kertesz, Horton,
Tibbetts, & Samet, 2006; Smith et al., 2000). Additionally, a comprehensive literature
review by Azar (2010) suggests that service utilization may be less consistent among
persons abusing alcohol than those abusing other drugs. The supportive inpatient status of
many participants at baseline may also help explain the higher-than-expected adherence
rates in this sample (Azar et al., 2010; Sylla, Bruce, Kamarulzaman, & Altice, 2007).
Eighty-three percent of participants in this study reported adequate adherence at baseline,
whereas in the intervention evaluation study by Margolin et al. (2003) baseline self-report
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measures of adherence were collected prior to entering a structured substance abuse
treatment program and only 51% reported adequate adherence.
Several strengths of this study are important to note. While all participants were
HIV-seropositive and had a history of alcohol abuse, the sample was still heterogeneous,
representing a diverse cross-section of hard-to-access, high-risk adults living in urban
Miami-Dade County. In addition, the intervention was highly comprehensive, offering
multiple topics relevant to HIV-positive alcohol abusers using cognitive remediation
strategies to improve efficacy for those with NCI. Both arms of the study were manualguided, ensuring treatment fidelity. Finally, process variables were integrated into this
study and the intervention design (National Institute of Mental Health Multisite HIV
Prevention Trial Group, 2001).
Unique features and limitations of this study should also be considered when
interpreting results. For ethical reasons, to ensure that participants in both arms received
equitable treatment benefit, the study required that the comparison condition offered a
healthy alternative to HHRP-A. A dose-effect analysis between groups could not be
conducted nor was it possible to determine which treatment components were most
effective. Similarly, participants in the HPC arm attended a significantly greater number
of sessions than the HHRP-A group. Although the two programs were designed to be
equivalent on both time and administration, the HPC group was condensed into two days
where the HHRP-A group was conducted over the course of several weeks, likely
contributing to greater absenteeism. Also, interpretation of findings may be limited by the
loss of over 30% of the sample by the 6-month follow-up time point. Finally, all
measures in this study were self-report. While both VL and adherence self-report

	
  

147

measures were checked for veracity by correlating measures with serum VL at baseline in
this study, it should nonetheless be noted that self-reported treatment adherence, in
particular, has been found to be inflated in some samples (Duran et al., 2001) and
adequately correlated with observational adherence measures in other studies (Shi et al.,
2010).
In conclusion, the results of this study suggest that treatment adherence and viral
load could be improved greatly by incorporating comprehensive, cognitive-behavioral
risk reduction interventions into HIV and substance abuse care. It is equally important
that interventions employ essential cognitive remediation strategies to further enhance
skills development and information retention among persons with HIV-related NC
impairment. The implementation and further translation of evidence-based interventions
require considerable time, effort and funding. Thus, the goal after finding an intervention
effective in community settings is to synthesize results for rapid dissemination to
clinicians and care providers in order to reduce the risk of HIV transmission and disease
progression on a public level (Copenhaver et al., 2012; Lyles, Crepaz, Herbst, & Kay,
2006).

	
  

148

REFERENCES
Allison, P. (2001). Missing Data. (pp. 3-5). Thousand Oaks: SAGE Publications.
Amico, K. R., Toro-Alfonso, J., & Fisher, J. (2005). An empirical test of the information,
motivation and behavioral skills model of antiretroviral therapy adherence. AIDS
Care, 17(6), 661–73. doi:10.1080/09540120500038058
Antinori, A., Arendt, G., Becker, J. T., Brew, B. J., Byrd, D. A., Cherner, M., … Wojna,
V. E. (2007). Updated research nosology for HIV-associated neurocognitive
disorders. Neurology, 69(18), 1789–99. doi:10.1212/01.WNL.0000287431.88658.8b
Antoni, M. H., Baggett, L., Ironson, G., LaPerriere, A., August, S., Klimas, N., …
Fletcher, M. a. (1991). Cognitive-behavioral stress management intervention buffers
distress responses and immunologic changes following notification of HIV-1
seropositivity. Journal of Consulting and Clinical Psychology, 59(6), 906–15.
Arno, P. S., Bonuck, K. A., Green, J., Fleishman, J., Bennett, C. L., Fahs, M. C., …
Drucker, E. (1996). The impact of housing status on health care utilization among
persons with HIV disease. Journal of Health Care for the Poor and Underserved,
7(1), 36–49. doi:10.1353/hpu.2010.0013
Azar, M. M., Springer, S. A., Meyer, J. P., & Altice, F. L. (2010). A systematic review of
the impact of alcohol use disorders on HIV treatment outcomes, adherence to
antiretroviral therapy and health care utilization. Drug and Alcohol Dependence,
112(3), 178–93. doi:10.1016/j.drugalcdep.2010.06.014
Bangsberg, D., Hecht, F., Charlebois, E., Zolopa, A., Holodniy, M., Sheiner, L., … Moss,
A. (2000). Adherence to protease inhibitors, HIV-1 viral load, and development of
drug resistance in an indigent population. AIDS, 14(4), 357–66.
Bangsberg, D., Perry, S., & Charlebois, E. (2001). Non-adherence to highly active
antiretroviral therapy predicts progression to AIDS. AIDS, 15(9), 1181–1183.
Bangsberg, D. R., Moss, A. R., & Deeks, S. G. (2004). Paradoxes of adherence and drug
resistance to HIV antiretroviral therapy. The Journal of Antimicrobial
Chemotherapy, 53(5), 696–9. doi:10.1093/jac/dkh162
Bass, J. K., Bornemann, T. H., Burkey, M., Chehil, S., Chen, L., Copeland, J. R. M., …
Patel, V. (2012). A United Nations General Assembly Special Session for mental,
neurological, and substance use disorders: the time has come. PLoS medicine, 9(1),
e1001159.

	
  

149

Baum, M. K., Rafie, C., Lai, S., Sales, S., Page, J. B., & Campa, A. (2010). Alcohol use
accelerates HIV disease progression. AIDS Research and Human Retroviruses,
26(5), 511–518.
Bowker, A. H. (1948). A test for symmetry in contingency tables. Journal of the
American Statistical Association, 43(244).
Braithwaite, S. R., & Bryant, K. J. (2010). Influence of alcohol consumption on
adherence to and toxicity of antiretroviral therapy and survival. Alcohol Research &
Health, 33(3), 280–287.
Bryant, K. J. (2006). Expanding research on the role of alcohol consumption and related
risks in the prevention and treatment of HIV/AIDS. Substance Use & Misuse, 41(1012), 1465–507. doi:10.1080/10826080600846250
Carpenter, C. C. J., Fischl, M. A., Hammer, S. M., Hirsch, M. S., Jacobsen, D. M.,
Katzenstein, D. A., … Volberding, P. A. (1997). Antiretroviral therapy for HIV
infection in 1997: Updated recommendations of the International AIDS Society USA Panel. Journal of the American Medical Association, 277(24), 1962–1969.
Carroll, K., Kadden, R., Donovan, D., Zweben, A., & Rounsaville, B. (1994).
Implementing treatment and protecting the validity of the independent variable in
treatment matching studies. Journal of Studies on Alcohol and Drugs, 12, 149.
Catz, S. L., Kelly, J. A., Bogart, L. M., Benotsch, E. G., & Mcauliffe, T. L. (2000).
Patterns , correlates , and barriers to medication adherence among persons
prescribed new treatments for HIV disease. Health Psychology, 19(2), 124–133.
doi:10.1037//0278Centers for Disease Control and Prevention Division of HIV/AIDS. (2012a). Estimated
HIV incidence in the United States, 2007–2010. HIV Surveillance Supplemental
Report 2012, 17(4). Retrieved from
http://www.cdc.gov/hiv/surveillance/resources/reports/2010supp_vol17no4/
Centers for Disease Control and Prevention Division of HIV/AIDS. (2012b). HIV
Surveillance Report, 2010 (Vol. 22). Retrieved from
http://www.cdc.gov/hiv/library/reports/surveillance/2011/surveillance_Report_vol_2
3.html
Cohen, S., Kamarck, T., & Mermelstein, R. (1983). A global measure of perceived stress.
Journal of Health and Social Behavior, 24(4), 385-396.
Cohen, S., & McKay, G. (1985). Social support, stress and the buffering hypothesis: A
theoretical analysis. In A. Baum, S. Talor, & J. Singer (Eds.), Handbook of
Psychology and Health (pp. 253–266). Hillsdale, NJ.

	
  

150

Cook, R., Sereika, S., Hunt, S., Woodward, W., Erlen, J., & Conigliaro, J. (2001).
Problem drinking and medication adherence among persons with HIV infection.
Journal of General Internal Medicine, 16(2), 83–8.
Deeks, S. G., Smith, M., Holodniy, M., & Kahn, J. O. (1997). HIV-1 protease inhibitors.
A review for clinicians. Journal of the American Medical Association, 277(2), 145–
53.
Dempster, A. P., Laird, N. M., & Rubin, D. B. (1977). Maximum likelihood from
incomplete data via the EM algorithm. Journal of the Royal Statistical Society,
Series B (, 1–38.
DiMatteo, M. R. (2004). Social support and patient adherence to medical treatment: a
meta-analysis. Health Psychology, 23(2), 207–18. doi:10.1037/0278-6133.23.2.207
Duran, S., Solas, C., Spire, B., Carrieri, M., Fuzibet, J., Costagliola, D., & Moatti, J.
(2001). Do HIV-infected injecting drug users over-report adherence to highly active
antiretroviral therapy? A comparison between patients’ self-reports and serum
protease inhibitor concentrations in the French Manif 2000 cohort study. AIDS,
15(8), 1075–81.
Farinpour, R., Martin, E. M., Seidenberg, M., Pitrak, D. L., Pursell, K. J., Mullane, K.
M., … Harrow, M. (2000). Verbal working memory in HIV-seropositive drug users.
Journal of the International Neuropsychological Society, 6(5), 548–55.
Fisher, J D, & Fisher, W. A. (1992). Changing AIDS-risk behavior. Psychological
Bulletin, 111(3), 455–74.
Fisher, Jeffrey D, Amico, K. R., Fisher, W. A., & Harman, J. J. (2008). The informationmotivation-behavioral skills model of antiretroviral adherence and its applications.
Current HIV/AIDS Reports, 5(4), 193–203.
Galvan, F., Bing, E., Fleishman, J., London, A., Caetano, R., Burnam, M., & Shapiro, M.
(2002). The prevalence of alcohol consumption and heavy drinking among people
with HIV in the United States: results from the HIV Cost and Services Utilization
Study. Journal of Studies on Alcohol and Drugs, 63(2), 179.
Gonzalez, J. S., Penedo, F. J., Antoni, M. H., Durán, R. E., McPherson-Baker, S.,
Ironson, G., … Schneiderman, N. (2004). Social support, positive states of mind,
and HIV treatment adherence in men and women living with HIV/AIDS. Health
Psychology, 23(4), 413–8. doi:10.1037/0278-6133.23.4.413
Heaton, R., Clifford, D., Franklin, D., Woods, S., Ake, C., Vaida, F., … Grant, I. (2010).
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral

	
  

151

therapy: CHARTER Study. Neurology, 75(23), 2087–96.
doi:10.1212/WNL.0b013e318200d727
Hinkin, C., Castellon, S., & Durvasula, R. (2002). Medication adherence among HIV+
adults Effects of cognitive dysfunction and regimen complexity. Neurology, 59(12),
1944–1950.
Howell, D. C. (2007). Statistical methods for psychology (6th ed.). Belmont, CA:
Thomson Wadsworth.
Hirokazu, Y., Wilson, P. A., Peterson, J. L., & Shinn, M. (2005). Multiple Pathways to
Community-Level Impacts in HIV Prevention: Implications for Conceptualization,
Implementation, and Evaluation of Interventions. In W. Trickett, E. J., & Pequegnat
(Ed.), Community Interventions and AIDS. New York: Oxford University Press.
IBM Corporation. (2010). IBM SPSS Base 19.0 for Windows User's Guide. IBM
Corporation, New York.
Kahana, S. Y., Rohan, J., Allison, S., Frazier, T. W., & Drotar, D. (2013). A metaanalysis of adherence to antiretroviral therapy and virologic responses in HIVinfected children, adolescents, and young adults. AIDS and Behavior, 17(1), 41–60.
doi:10.1007/s10461-012-0159-4
Kim, T. W., Kertesz, S. G., Horton, N. J., Tibbetts, N., & Samet, J. H. (2006). Episodic
homelessness and health care utilization in a prospective cohort of HIV-infected
persons with alcohol problems. BMC Health Services Research, 6, 19.
doi:10.1186/1472-6963-6-19
Lehavot, K., Huh, D., Walters, K. L., King, K. M., Andrasik, M. P., & Simoni, J. M.
(2011). Buffering effects of general and medication-specific social support on the
association between substance use and HIV medication adherence. AIDS Patient
Care and STDs, 25(3), 181–9. doi:10.1089/apc.2010.0314
Little, R. J. (1988). A test of missing completely at random for multivariate data with
missing values. Journal of the American Statistical Association, 83(404), 1198–
1202.
Lopez, C., Antoni, M., Penedo, F., Weiss, D., Cruess, S., Segotas, M.-C., … Fletcher, M.
A. (2011). A pilot study of cognitive behavioral stress management effects on stress,
quality of life, and symptoms in persons with chronic fatigue syndrome. Journal of
Psychosomatic Research, 70(4), 328–34. doi:10.1016/j.jpsychores.2010.11.010

	
  

152

Lucas, G. M. (2005). Antiretroviral adherence, drug resistance, viral fitness and HIV
disease progression: a tangled web is woven. The Journal of Antimicrobial
Chemotherapy, 55(4), 413–6. doi:10.1093/jac/dki042
Lutgendorf, S. K., Antoni, M. H., Ironson, G., Starr, K., Costello, N., Zuckerman, M., …
Schneiderman, N. (1998). Changes in cognitive coping skills and social support
during cognitive behavioral stress management intervention and distress outcomes
in symptomatic human immunodeficiency virus (HIV)-seropositive gay men.
Psychosomatic medicine, 60(2), 204–14.
Malow, R., Devieux, J., Stein, J., Rosenberg, R., Lerner, B., Attonito, J., & Villalba, K.
(2012). Neurological function, information-motivation-behavioral skills factors, and
risk behaviors among HIV-positive alcohol users. AIDS and Behavior, 16(8), 2297–
308. doi:10.1007/s10461-012-0246-6
Mannheimer, S. B., Morse, E., John, P., & Andrews, L. (2006). Sustained Benefit From a
Long-Term Antiretroviral Adherence Intervention. Journal of Acquired Immune
Deficiency Syndromes, 43, 41–47.
Mannheimer, SB, Matts, J., Telzak, E., & Chesney, M. (2010). Psychological and Sociomedical Aspects of AIDS / HIV Quality of life in HIV-infected individuals receiving
antiretroviral therapy is related to adherence. AIDS Care, 17(1), 10–22.
Mannheimer, Sharon, Friedland, G., Matts, J., Child, C., & Chesney, M. (2002). The
consistency of adherence to antiretroviral therapy predicts biologic outcomes for
human immunodeficiency virus-infected persons in clinical trials. Clinical Infectious
Diseases, 34(8), 1115–21. doi:10.1086/339074
Margolin, A., Avants, S., Warburton, L., Hawkins, K., & Shi, J. (2003). A randomized
clinical trial of a manual-guided risk reduction intervention for HIV-positive
injection drug users. Health Psychology, 22(2), 223–228. doi:10.1037/02786133.22.2.223
Marx, K. A., Malka, E. S., Ravishankar, J., & Schwartz, R. M. (2011). Measurement of
retention in care among adults infected with HIV in an urban clinic. AIDS care,
23(10), 1298–304. doi:10.1080/09540121.2011.555942
McLellan, A., Alterman, A., Cacciola, J., Metzger, D., & O’Brien, C. (1992). A new
measure of substance abuse treatment initial studies of the treatment services review.
The Journal of Nervous and Mental Disease, 180(2), 101–110.
Mclellan, A. T., Zanis, D., Incmikoski, R., Parikh, G., Stevens, G., & Brock, M. (1989).
Administration Manual for the Treatment Services Review “TSR.” Washington, DC.

	
  

153

Miller, L. (1993). Psychotherapy of the Brain-Injured Patient: Reclaiming the Shattered
Self. WW Norton & Co. Inc.
Miller, W., & Rollnick, S. (1991). Motivational Interviewing: Preparing People to
Change Addictive Behavior. New York: Guilford Press.
Mugavero, M. J., Amico, K. R., Westfall, A. O., Crane, H. M., Kitahata, M., & Saag, M.
S. (2013). Early retention in HIV care and viral load supression: Implications for a
test and treat approach to HIV prevention. Journal of Acquired Immune Deficiency
Syndromes, 59(1), 86–93. doi:10.1097/QAI.0b013e318236f7d2.Early
Mugavero, M. J., Raper, J. L., Reif, S., Whetten, K., Leserman, J., Thielman, N. M., &
Pence, B. W. (2009). Overload: impact of incident stressful events on antiretroviral
medication adherence and virologic failure in a longitudinal, multisite human
immunodeficiency virus cohort study. Psychosomatic Medicine, 71(9), 920–6.
doi:10.1097/PSY.0b013e3181bfe8d2
National HIV/AIDS Strategy Implementation Plan. (2010). Washington, DC. Retrieved
from http://www.whitehouse.gov/sites/default/files/uploads/NHAS.pdf
National Institute of Mental Health Multisite HIV Prevention Trial Group. (2001).
Social-cognitive theory mediators of behavior change in the National Institute of
Mental Health Multisite HIV Prevention Trial. Health Psychology, 20(5), 369–376.
doi:10.1037//0278-6133.20.5.369
Ownby, R., Waldrop-Valverde, D., Caballero, J., & Jacobs, R. (2013). Baseline
medication adherence and response to an electronically delivered health literacy
intervention targeting adherence. Neurobehavioral HIV Medicine, 4, 113–121.
doi:10.2147/NBHIV.S36549.Baseline
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A.,
… Holmberg, S. D. (1998). Declining morbidity and mortality among patients with
advanced human immunodeficiency virus infection. The New England Journal of
Medicine, 338(13), 853–860.
Paterson, D., Swindells, S., Mohr, J., Brester, M., Vergis, E., Squier, C., … Singh, N.
(2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV
infection. Annals of Internal Medicine, 133(1), 21–30.
Richardson, J. T. E. (2011). Eta squared and partial eta squared as measures of effect size
in educational research. Educational Research Review, 6(2), 135–147.
doi:10.1016/j.edurev.2010.12.001
Rothlind, J. C., Greenfield, T. M., Bruce, A. V, Dieter, J., Flenniken, D. L., Lindgren, J.
A., & Michael, W. (2005). Heavy alcohol consumption in individuals with HIV

	
  

154

infection: Effects on neuropsychological performance. Journal of the International
Neuropsychological Society, 11(1), 70–83.
Sacktor, N. (2002). The epidemiology of human immunodeficiency virus-associated
neurological disease in the era of highly active antiretroviral therapy. Journal of
Neurovirology, 8 Suppl 2, 115–21. doi:10.1080/13550280290101094
Sarason, I., Johnson, J., & Siegel, J. (1978). Assessing the impact of life changes:
Development of the Life Experiences Survey. Journal of Consulting and Clinical
Psychology, 46(5), 392–46.
Sherbourne, C., & Stewart, A. (1991). The MOS Social Support Survey. Social Science
& Medicine, 32(6), 705–714.
Shi, L., Liu, J., Koleva, Y., Fonseca, V., Kalsekar, A., & Pawaskar, M. (2010).
Concordance of adherence measurement using self-reported adherence
questionnaires and medication monitoring devices. PharmacoEconomics, 28(12),
1097–107. doi:10.2165/11537400-000000000-00000
Simoni, J. M., Frick, P. A, Lockhart, D., & Liebovitz, D. (2002). Mediators of social
support and antiretroviral adherence among an indigent population in New York
City. AIDS Patient Care and STDs, 16(9), 431–9.
doi:10.1089/108729102760330272
Simoni, J. M., Frick, P. A., & Huang, B. (2006). A longitudinal evaluation of a social
support model of medication adherence among HIV-positive men and women on
antiretroviral therapy. Health Psychology, 25(1), 74–81. doi:10.1037/02786133.25.1.74
Simoni, J. M., Kurth, A. E., Pearson, C. R., Pantalone, D. W., Merrill, J. O., & Frick, P.
A. (2006). Self-report measures of antiretroviral therapy adherence: A review with
recommendations for HIV research and clinical management. AIDS and Behavior,
10(3), 227–45. doi:10.1007/s10461-006-9078-6
Singh, N., Berman, S. M., Swindells, S., Justis, J. C., Mohr, J. A., Squier, C., & Wagener,
M. M. (1999). Adherence of human immunodeficiency virus-infected patients to
antiretroviral therapy. Clinical infectious Diseases, 29(4), 824–30.
doi:10.1086/520443
Smith, L. R., Fisher, J. D., Cunningham, C. O., & Amico, K. R. (2012). Understanding
the behavioral determinants of retention in HIV care: a qualitative evaluation of a
situated information, motivation, behavioral skills model of care initiation and
maintenance. AIDS Patient Care and STDs, 26(6), 344–55.
doi:10.1089/apc.2011.0388

	
  

155

Smith, M. Y., Rapkin, B. D., Winkel, G., Springer, C., Chhabra, R., & Feldman, I. S.
(2000). Housing status and health care service utilization among low-income
persons with HIV/AIDS. Journal of General Internal Medicine, 15(10), 731–8.
Starace, F., Massa, A., Amico, K. R., & Fisher, J. D. (2006). Adherence to antiretroviral
therapy: an empirical test of the information-motivation-behavioral skills model.
Health Psychology, 25(2), 153–62. doi:10.1037/0278-6133.25.2.153
Sylla, L., Bruce, R. D., Kamarulzaman, A., & Altice, F. L. (2007). Integration and colocation of HIV/AIDS, tuberculosis and drug treatment services. The International
Journal on Drug Policy, 18(4), 306–12. doi:10.1016/j.drugpo.2007.03.001
Tabachnick, B. G., & Fidell, L. S. (2007). Using multivariate statistics (5th ed.). Boston:
Allyn and Bacon.
Tesoriero, J., French, T., Weiss, L., Waters, M., Finkelstein, R., & Agins, B. (2003).
Stability of adherence to highly active antiretroviral therapy over time among clients
enrolled in the treatment adherence demonstration project. Journal of Acquired
Immune Deficiency Syndromes, 33(4), 484–93.
Thompson, M., Aberg, J., & Hoy, J. (2012). Antiretroviral treatment of adult HIV
infection 2012 recommendations of the International Antiviral Society–USA Panel.
Journal of the American Medical Association, 308(4).
Volkow, N., & Montaner, J. (2010). Enhanced HIV testing, treatment, and support for
HIV-infected substance users. Journal of the American Medical Association,
303(14), 1423–1424.
Wong, M. D., Sarkisian, C. a, Davis, C., Kinsler, J., & Cunningham, W. E. (2007). The
association between life chaos, health care use, and health status among HIVinfected persons. Journal of General Internal Medicine, 22(9), 1286–91.
doi:10.1007/s11606-007-0265-6

	
  

156

CHAPTER VI
SUMMARY OF CONCLUSIONS
The overarching purpose of the three studies comprising this dissertation was to
investigate the extent to which biopsychosocial factors—including NC impairment —
influence ART adherence, service utilization and VL before and after the delivery of an
evidence-based intervention among HIV-positive alcohol abusers. Each study built upon
information gained in the preceding study, concluding with the final analysis which
evaluated the effectiveness of the HHRP-A intervention. The HHRP-A intervention is
unique in two ways: first, it is delivered using a holistic, harm-reduction approach,
addressing multiple, complex psychosocial factors prevalent in the lives of people who
abuse drugs or alcohol; second, the intervention includes cognitive remediation strategies
to maximize information retention and synthesis for PLWH who may also suffer from a
degree of neurocognitive impairment.
The first study examined factors hypothesized to contribute to NCI: drug and
alcohol use and time living with HIV. This baseline analysis, using structural equation
modeling, positioned five exogenous variables—years living with HIV; time from HIV
diagnosis to seeking care; and days using alcohol, marijuana and cocaine in the prior
three months—as predictors of three NC measures selected to address a range of
cognitive domains. Mean scores on NC measures for this sample were significantly lower
than mean normative scores suggesting a degree of impairment. In addition, both
marijuana use and years living with HIV were associated with poorer scores on the CTT2
which measures several executive functions including information processing.
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The second study also used structural equation modeling at baseline to test a
biopsychosocial model predicting VL with ART adherence as a mediator. Independent
variables included tangible social support, barriers to ART adherence, and stress.
Moderators included alcohol use, marijuana use and NC impairment. Employing Baron
and Kenny’s 4-step approach to testing mediation (Baron & Kenny, 1986; James & Brett,
1984; Judd & Kenny, 1981), the relationship between barriers to adherence and VL was
found to be to a considerable degree mediated by ART adherence.
The final study was a randomized controlled trial, modeled after the research
conducted by Margolin et al. (2003) who conducted a previous assessment of the HHRP
intervention adapted for PLWH who were intravenous drug users enrolled in a
methadone maintenance program. Participants were randomized to the HHRP-A or a
comparison group and data were collected at baseline, post-intervention, 3-month, and 6month follow-up time points. Participants in the HHRP-A condition were significantly
more likely to report optimal ART adherence and undetectable VL at 6 months postintervention. A significant time-by-condition effect was also observed in social support,
with the experimental condition showing greater improvement than the comparison
group.
Some limitations and strengths of this research are important to note. These
participants were drawn from clinical sites and may not be representative of PLWH who
are not engaged in care for HIV. Reporting bias should be considered in interpreting
outcomes; this proportion of participants who were engaged in care may also account for
the relatively high adherence rates reported in this sample. Nearly a quarter of the sample
was in residential addictions treatment at baseline and it is possible that recent substance
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use was underreported or atypically low for the group. Measurement issues should be
considered when interpreting this study’s results. A battery of only three NC assessment
instruments were used which may limit the sensitivity for finding NC impairment. Also,
ART adherence was a self-reported measure which could provide an underestimate of
actual adherence rates. This research also had several strengths. The sample was highly
heterogeneous, contributing to the external validity of the outcomes. In addition, the
HHRP-A intervention assessed in Aim 3 was manual-guided contributing to the internal
validity of outcomes.
Overall findings from the three studies suggest that: (a) marijuana and time living
with HIV may be important contributors to NC impairment among PLWH; (b) a
biopsychosocial model can be an effective tool for understanding factors that contribute
to changes in ART adherence and VL; and (c) providing comprehensive health promotion
interventions such as HHRP-A particularly those incorporating cognitive remediation
strategies, could improve health outcomes for HIV-seropositive substance users. Future
research should further investigate possible substance use and HIV-related factors (as
well as interactions between these variables) contributing to NC impairment. Greater
understanding of psychosocial variables and their direct effect upon viral suppression and
disease progression among PLWH is also needed. Finally, health outcomes for PLWH
could be improved by the ongoing delivery, evaluation and adaptation of holistic,
evidence-based interventions that address the complex medical, psychological, cognitive,
and social needs of PLWH who use alcohol and other drugs.
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Appendix 1: HHRP Fact sheet
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APPENDIX 2: recruitment sites accessed by parent study

1. Borinquen Health Care Center*
2. Florida Department of Health: Broward County Department Sexually Transmitted
Disease Program
3. Center for Haitian Studies
4. South Florida Provider Coalition
5. The Salvation Army
6. Care Resource
7. Empower U, Inc.*
8. The Village*
9. South Florida AIDS Network
10. The Center for Positive Connections Support & Resource Center
11. South Beach AIDS Project, Inc.
12. Miami Beach Community Health Center, Inc.
13. Helen B. Bentley Family Health Center, Inc.

*Indicates sites from where the majority of participants were recruited.
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APPENDIX 3: additional Tables and Figures for Manuscript 1

Figure Appendix 3.1. Hypothesized directional model with one proposed latent
variable

Table Appendix 3.1. Correlation matrix for all variables in the model (N=370)
AVLT

CTT2

SCT

Alcohol

Marijuana

Cocaine

AVLT1
1.000
CTT22
-0.293
1.000
SCT3
-0.206
0.174
1.000
Alcohol
-0.040
0.002
0.070
1.000
Marijuana
0.061
0.070
-0.016
0.171
1.000
Cocaine
0.003
-0.038
0.051
0.386
0.195
1.000
Yrs HIV4
-0.087
0.176
0.095
0.081
-0.056
0.046
Dx to Tx5
0.030
0.002
-0.038
0.021
0.139
0.012
1
AVLT Auditory Verbal Learning Test
2
CTT2 Color Trails Test 2
3
SCT Short Category Test
4
Yrs. HIV Duration of known HIV infection in years
5
Dx. to Tx Years between diagnosis of HIV infection and initiation of ART
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Yrs HIV1

1.000
0.246

Dx to
Tx2

1.000

APPENDIX 4: ADDITIONAL FIGURE FOR MANUSCRIPT 2

Figure Appendix 4.1. Hypothesized partially mediated model predicting viral load,
moderated by cognitive and behavioral factors (N=246)
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APPENDIX 5: ADDITIONAL FIGURES FOR MANUSCRIPT 3

Figure Appendix 5.1. Mean number of services utilized at each time point (N=243)

Time Point

Figure Appendix 5.2. Mean support scores, all time points (N=243)

Time Point
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Figure Appendix 5.3. Mean stress scores at T1, T3 and T4 (N=243)

Time Point

Figure Appendix 5.4. Percent participants reporting >95% adherence to ART at
each time point. N=243

Time Point
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Figure Appendix 5.5. Proportion of participants reporting undetectable VL at each
time point (N=243)

Time Point
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